CA2128242C - Moulded bodies, in particular pellets, containing one or more plant extracts, and the pharmaceutical or cosmetic use of such pellets - Google Patents
Moulded bodies, in particular pellets, containing one or more plant extracts, and the pharmaceutical or cosmetic use of such pelletsInfo
- Publication number
- CA2128242C CA2128242C CA002128242A CA2128242A CA2128242C CA 2128242 C CA2128242 C CA 2128242C CA 002128242 A CA002128242 A CA 002128242A CA 2128242 A CA2128242 A CA 2128242A CA 2128242 C CA2128242 C CA 2128242C
- Authority
- CA
- Canada
- Prior art keywords
- plant
- gelatin
- pellets
- plant extract
- shaped article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008188 pellet Substances 0.000 title claims abstract description 105
- 239000000419 plant extract Substances 0.000 title claims abstract description 66
- 239000002537 cosmetic Substances 0.000 title claims abstract description 22
- 229920000159 gelatin Polymers 0.000 claims abstract description 69
- 108010010803 Gelatin Proteins 0.000 claims abstract description 66
- 239000008273 gelatin Substances 0.000 claims abstract description 66
- 235000019322 gelatine Nutrition 0.000 claims abstract description 66
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 66
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 57
- 102000008186 Collagen Human genes 0.000 claims abstract description 48
- 108010035532 Collagen Proteins 0.000 claims abstract description 48
- 229920001436 collagen Polymers 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000011159 matrix material Substances 0.000 claims abstract description 42
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 40
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 40
- 230000008569 process Effects 0.000 claims abstract description 40
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 35
- 239000007787 solid Substances 0.000 claims abstract description 34
- 108010064851 Plant Proteins Proteins 0.000 claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 33
- 235000021118 plant-derived protein Nutrition 0.000 claims abstract description 33
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 239000006185 dispersion Substances 0.000 claims abstract description 7
- 239000007789 gas Substances 0.000 claims abstract description 7
- 244000186892 Aloe vera Species 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 241000196324 Embryophyta Species 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 239000000470 constituent Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- 102000016942 Elastin Human genes 0.000 claims description 15
- 108010014258 Elastin Proteins 0.000 claims description 15
- 229920002549 elastin Polymers 0.000 claims description 15
- 229920002521 macromolecule Polymers 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 10
- 239000004014 plasticizer Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- 239000012675 alcoholic extract Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019426 modified starch Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 4
- 244000215068 Acacia senegal Species 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 241000206672 Gelidium Species 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 230000000873 masking effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 235000013305 food Nutrition 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000007493 shaping process Methods 0.000 abstract description 3
- 244000144927 Aloe barbadensis Species 0.000 description 38
- 239000000341 volatile oil Substances 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 18
- 238000001035 drying Methods 0.000 description 18
- -1 for example Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 10
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 10
- 235000005493 rutin Nutrition 0.000 description 10
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 10
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 10
- 229960004555 rutoside Drugs 0.000 description 10
- 229930003427 Vitamin E Natural products 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 9
- 235000019165 vitamin E Nutrition 0.000 description 9
- 229940046009 vitamin E Drugs 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 235000014134 echinacea Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 244000133098 Echinacea angustifolia Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000413 hydrolysate Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 241000518994 Conta Species 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000010685 fatty oil Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000010647 garlic oil Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 235000020344 instant tea Nutrition 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 206010041303 Solar dermatitis Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229940075911 depen Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011252 protective cream Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000208698 Drosera Species 0.000 description 1
- 240000004530 Echinacea purpurea Species 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241001456088 Hesperocnide Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000514697 Lepidothamnus laxifolius Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001126925 Lobata Species 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 241000198694 Passiflora pallida Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 244000062780 Petroselinum sativum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000010450 Pino mugo Nutrition 0.000 description 1
- 235000016787 Piper methysticum Nutrition 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000000497 Primula Nutrition 0.000 description 1
- 241000245063 Primula Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000061121 Rauvolfia serpentina Species 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000003591 Tagetes lucida Nutrition 0.000 description 1
- 240000002670 Tagetes lucida Species 0.000 description 1
- 241000985696 Tecoma Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 241001530097 Verbascum Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- WKACQPMBGWZDMR-UHFFFAOYSA-N Vincamin Natural products CC=C1/CN2CCC34CC2C1C(=C3Nc5ccccc45)C=O WKACQPMBGWZDMR-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- KTFZDGGBFILTSA-UHFFFAOYSA-N beta-Sitosterin Natural products CCC(CC)CCC(C)C1CCC2C1CCC3C2CC=C4CC(O)CCC34C KTFZDGGBFILTSA-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940112478 crataegus extract Drugs 0.000 description 1
- 239000010108 crataegus extract Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940068560 greater celandine Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000012432 intermediate storage Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000001851 juniperus communis l. berry oil Substances 0.000 description 1
- 150000002559 kavalactones Chemical class 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001098 melissa officinalis l. leaf oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940040493 myrtol Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000590 phytopharmaceutical Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 108010013480 succinylated gelatin Proteins 0.000 description 1
- 229940007079 succinylated gelatin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013706 tagetes lucida Nutrition 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Shaped articles containing plant extract(s), in particular pellets, are formed by dispersing the plant extract(s) in a matrix predominantly composed of a skeleton builder, i.e. collagen, gelatin, fractionated gelatin, a collagen hydrolysate, a gelatin derivative, plant protein or plant protein hydrolysate. They are storage-stable, and their pharmacological and cosmetic characteristics are essentially unaltered in comparison with the native extract. They are prepared by a simple process in which liquid plant extract(s) is(are) mixed or emulsified in a solution of the skeleton builder, or solid extracts are dissolved or suspended in a solution of the skeleton builder, the dispersion of skeleton builder and plant extract(s) is added dropwise to an intensely cold, inert, liquefied gas, preferably liquid nitrogen, thus shaping the pellets, and the shaped pellets are dried. The plant extract employed is preferably Aloe vera juice.
Description
M:AL2740B 18.1.1993 - Z128242 Shaped articles contA;n;ng plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use The present invention relates to pellets or true spheres contA;n;ng plant extract(s) and which comprise a dispersion of the plant extract in a matrix predominantly composed of a skeleton builder of a hydrophilic macromolecule.
The invention furthermore relates to a mild process for the preparation of such pellets or true spheres and to their pharmaceutical, peroral or cosmetic application.
The plant extract which is preferably employed is Aloe vera juice.
The plant extracts in the sen~e of the present invention are juices from fresh plants obtained directly from the plant, pressed-out juices from fresh plants, either in the original concentration or in concentrated form, filtered and unfiltered, hydrophilic extracts (aqueous or alcoholic extracts, for example ethanol extracts or 1,2-propylene glycol extracts) such as, for example, original tinctures in homeopathy, fluid extracts, macerates, lipophilic extracts (such as, for example, garlic oil), essential oils, complete extracts or specifically stAn~Ardized extracts (for example stAn~rdized to a specific flavone glycoside content), essential oil extracts, individually isolated plant constituents (such as, for example, rutin), synthetic analogs (such as, for example, perfume oils, camphor, thymol, vanillin) and derivatized plant constituents (such as, for example, aglycones).
In individual cases, it is also possible to use dry extracts or the redissolved extract from a dry extract in a suitable solvent, or decoctions prepared therefrom. Pulverized drug constituents (for example leaves, roots, herbaceous parts) can also be processed.
Being natural substances, plant extracts are frequently sensitive to external factors such as light, M:AL2740B 18.1.1993 - 2 -oxidation by atmospheric oxygen, heat, p~ effects in solutions, or microbial contamination. In many plant-derived active substances, it is known that only the fresh juice obtained originally from the plant or parts thereof (for example Echinacea pressed-out juice or Aloe vera juice) have optimum activity. Each means of preser-vation, such as drying by heat, chemical preservation, heat treatment for preservation purposes and the like adversely affect the delicate plant constituents with regard to their chemical structure and thus their activ-ity. In most cases, preservation against microbial cont~mination is unavoidable when using fresh plant juices so as to achieve at least limited shelf life.
In addition, the dry matter content of such fresh plant juices is very low, and a large amount of water is being transported or stored.
Lipophilic plant extracts which are sensitive to oxidation, such as vitamin E or garlic oil, are difficult to store in unaltered form and usually have to be pro-cessed at once.
Essential oils are volatile and difficult tohandle in the form of liquids.
Aloe vera (Aloe barbadensis Miller; synonyms:
Aloe vera Tournefort et Linné, Aloe vulgaris Lamarck) has been used for a long time in traditional medicine of those regions in which this plant, which belongs to the family of the Liliaceae grows wild.
If used externally, the gel-like plant juice has, for example, a beneficial effect on wound healing, acts as an antibiotic or has a softening effect on the skin.
Aloe vera juice can be administered internally in the treatment of gastric diseases and disorders of the gastrointestinal tract. Anti-inflammatory properties have also been reported.
These original findings have led to large planta-tions of Aloe vera having been established in Central America, South America and parts of North America. The juice in the leaves is obtained at the site itself in a laborious process and subsequently concentrated under the Z~28242 M:AL2740B 18.1.1993 - 3 -mildest possible conditions. The concentration of plant constituents in the freshly obtained juice is between 0.3 and approximately 1 %. Fresh Aloe vera fillets, aqueous concentrates or spray- or freeze-dried goods are all commercially available. The differences in quality of commercially available products are considerable with regard to stability and composition and depend largely on the preparation technology employed.
Aqueous concentrates or the juice from the leaves are currently being used successfully in dermatoses (for example burns by the action of heat, W rays or X-rays), chemical burns, wounds, gastric diseases or parodontosis.
It appears that the pharmacological effect is only to be attributed to the total of all constituents. A demonstra-tion of the effect of individual components is currentlybeing investigated extensively.
However, since no undesired side-effects of Aloe vera juice are known, this natural product has been offered for sale for many years in creams, moisturizing emulsions, sun care products or for internal use.
The shelf life, or stability of storage, of the aqueous plant gel causes substantial difficulties.
Despite preservation, the liquid product is unstable to the action of heat and pH, sensitive to oxygen and, moreover, highly susceptible to microbial contamination.
The transport of fresh Aloe vera juice is diffi-cult and costly due to the high liquid volume - 90-99 %
of water are transported - and the abovementioned insta-bility phenomena. Moreover, the juice must be cooled until it is used in production. The preparation methods which involve the process steps initial washing of the leaves, obtA;ning the fillets, homogenization, purifica-tion and filtration, concentration and drying, can result in changes in the constituents and bacterial contamina-tion of the end product in question if the technologyused is unsuitable.
Aloe vera powders obtained by spray- or freeze-drying are only sparingly redissolvable in cold water since they lack wettability and because there is a danger ZlZ8Z42 M:AL2740B 18.1.1993 - 4 -of lump formation. Moreover, freeze-dried products are hygroscopic and easily form lumps when stored inade-quately. Commercially available products which are readily dissolvable in water are frequently treated with surfactants, which are undesired in cosmetics.
It is therefore an object of the invention to provide unpreserved, storage-stable, concentrated, solid or semi-solid forms of plant extracts, in particular of Aloe vera juice, which can be redissolved without problem and whose pharmacological and cosmetic properties remain unaltered compared with the native plant juice.
This object is achieved according to the inven-tion by pellets contA;ning plant extract, which comprise a dispersion of the plant extract in a matrix contA;n;ng predominantly a skeleton builder of a hydrophilic macromolecule.
The following are employed as hydrophilic macromolecules: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant pro-teins, plant protein hydrolysates, elastin hydrolysates;and mixtures of the abovementioned substances.
This object is furthermore achieved by a process for the preparation of pellets contAining plant extract(s), which comprises mixing or emulsifying the skeleton builder in solid or dissolved form with liquid plant extract, or dissolving or suspending solid extracts in a solution of the skeleton builder and making the product into shaped articles. If required, the shaped articles can be dried.
The only aspect that requires attention is that matrix systems and active substance must not be incompatible.
In particular, the present invention provides shaped articles contAining a plant extract, which com-prise a dispersion of the plant extract in a matrix composed predominantly of a skeleton builder of hydro-philic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, elastin hydrolysates, plant proteins, plant protein hydrolysates; and their Z~Z8~4Z
M:AL2740B 18.1.1993 - 5 -mixtures.
The present invention furthermore provides aprocess for the preparation of shaped articles cont~ining plant extract, wherein a) a skeleton builder of hydrophilic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolys-ates, gelatin derivatives, plant proteins, plant protein hydrolysates, elastin hydrolysates; and their mixtures, .
is mixed with plant extracts selected from the group consisting of:
hydrophilic liquid plant extracts, aqueous extracts, alcoholic extracts; and their mixtures; and b) the resulting mixture of skeleton builder and plant extract is added dropwise to an intensely cold inert liquid, thus making it into shaped articles.
Preferred embodiments of the invention are described and claimed in the subclaims.
The following are examples of plant extracts or of extracts or individual substances obtained therefrom:
Flavonoids and their aglycones:
rutin, quercetin, diosmin, hyperoside, (neo)hesperidin, hesperitin, Ginkgo biloba (for example ginkgo flavone glycosides), Crataegus extract (for example oligomeric procyanidines), buckwheat (for example rutin), Sophora japonica (for example rutin), birch leaves (for example quercetin glycosides, hyperoside and rutin), elderflower (for example rutin), lime flower (for example essential oil contAining quercetin and farnesol), St John's wort oil (for example olive oil extract), calendula, arnica (for example oily extracts of the flowers with essential oil, polar extracts with flavonoids), balm (for example flavones, essential oil), M:AL2740B 18.1.1993 - 6 - 2128~42 Essential oils:
sage (for example essential oil cont~ining thymol), aniseed (for example essential oil cont~ining trans-anethol), oil of cloves (for example essential oil cont~;n;ng eugenol), camomile (for example chamazulene, alpha-bisabolol), myrtol: (limonene, alpha-pinene, cineol), oil of peppermint (for example oil cont~;n;ng menthol), caraway (for example oil cont~;ning carvone), dwarf pine oil (for example oil contAin;ng alpha-pinene), juniper, rosemary, eucalyptus oil, lavender, fir leaf oil, bergamot oil, citrus oil, balm, marjoram, thyme, basil (stomachic tonics or condiments), fennel Fatty oils:
for example wheatgerm oil and vitamin E isolated there-from, oil of evening pri~rose (for example gamma-linolenic acid), plant lecithins (for example soybean lecithin), sphingolipids/ceramides isolated from plants Immunostimulants:
Echinacea purpurea (for example alcoholic extracts, fresh plant juice, pressed-out juice), Eleutherococcus senti-cosus Alkaloids:
rauwolfia (for example prajmalin), periwinkle (for example vincamin) Other phytopharmaceuticals:
aloe, horse chestnut (for example aescin), garlic (for example garlic oil), pineapple (for example bromelains), ginseng (for example ginsenosides), Our Lady's thistle fruit (for example extract st~n~rdized with regard to silymarin), box holly root (for example ruscogenin),valerian (for example valepotriates, Tct. Valerianae), kava kava (for example kavalactones), hop flowers (for example hop bitters), Extr. Passiflorae, gentian (for example ethanolic extract), anthraquinone-cont~ining drug extracts, for example aloin-cont~ining Aloe vera juice, pollen extract, extracts from algae, licorice extracts, palm extract, galphi~ia (for example original tincture), mistletoe (for example aqueous ethanolic extract), phyto-sterols (for example beta-sitosterin), verbascum (for M:AL2740B 18.1.1993 --7 - 2128242 example aqueous-alcoholic extract), drosera (for example vinum liquorosum extract), sea buckthorn fruit (for example juice obtained therefrom or sea buckthorn oil), marshmallow root, primula root extract, fresh plant extracts of mallow, comfrey, ivy, horsetail, yarrow, ribwort (for example pressed-out juice), stinging nettle, greater celandine, parsley.
Plant extracts of Norolaena lobata, Tagetes lucida, Tecoma siems, Momordica charantia.
As a rule, the plant extract is generally selected from the group consisting of: solid plant extracts, liquid plant extracts, hydrophilic plant extracts, lipophilic plant extracts, individual plant constituents; and mixtures of these.
In general, the literature mentions Aloe vera juice, Aloe vera gel and Aloe vera extracts. The term "Aloe vera juice" used in the sense of the invention is to be understood as meaning, in general, the native juice obtained directly from the leaf, the filtered or purified juice, the juice which has been concentrated under mild conditions and also the redissolved juice made of a dry extract. For internal use, it is also possible to use the whole leaf, leaf constituents and flowers in homogenized form. Alternatively, individual constituents may be suitable for specific uses.
The pellets according to the invention are spherical, uniform shaped articles whose diameters have a customary range of 0.8 - 2 mm. Moreover, sizes of 0.2 -0.8 and 2 - 12 mm can be prepared according to the invention. Pellets with a diameter of over 2 mm are termed true spheres in the present invention, and they are suitable as single unit dosage form.
Surprisingly, the pellets display a great mechanical strength combined with a low degree of abrasion (friability). They are storage-stable, can be metered readily and are obtained as a free-flowing material due to the specific preparation process. They can contain plant extract(s) at concentrations of 0.1 - 98 % (percent by weight), preferably 0.1 - 60 %, 21Z~42 M:AL2740B 18.1.1993 - 8 -calculated as solids.
Surprisingly, neither the nature nor the composition of the constituents of the native plant con-stituents are altered by the pellets according to the invention. As a cold process, the process according to the invention is a very mild form of processing. The pellets cont~;ning plant extract(s) can exist in the form of a lyophilisate or in the form of solid or gel-like pellets, depen~;ng on the preparation.
Preservatives or a heat treatment for preserva-tion purposes can be dispensed with by conversion into pellet form, using the matrix systems according to the invention.
A pelleted fresh plant juice is storage-stable.
If, for example, solvent extraction is required for stability reasons, this can be dispensed with.
Furthermore, liquids can be converted into the solid form (essential oils or fatty oils). This improves storage stability, transportability and the handling quality of such substances.
The pellets, which have been dried conventionally according to the invention, with or without addition of plasticizers, can be recognized easily by their characteristic, typical appearance: they are transparent or opalescent.
The product according to the invention can be employed directly for pharmaceutical purposes, for internal use or for cosmetic purposes.
For pharmaceutical purposes, the pellets, as multiple unit dosage forms, can be filled into sachets or hard gelatin capsules in the form of granules, further-more in the form of beverage granules for the preparation of drink solutions (for example instant teas), and they can be packaged as single unit dosage forms, i.e. single unit dose pellets for example filled into suitable containers, blister packs or dosing dispensers for withdrawing them singly. A further single unit form is represented by rapidly dissolving tablets made by compressing freeze-dried pellets.
21Z8;~
M:AL2740B 18.1.1993 - 9 -For cosmetic uses, it is particularly advantage-ous according to the invention to use plant proteins or hydrolysates thereof, soluble collagen, gelatin, collagen hydrolysates, elastin or elastin hydrolysates as carrier materials of the shaped articles.
Gelatin is a scleroprotein obtained from collagen-cont~;n;ng material, and its properties vary depending on the preparation process. It is composed essentially of four molecular weight fractions which have an effect on physicochemical properties as a function of the molecular weight and the percentage by weight. For example, the more microgel (107 to 108 D) present, the higher the viscosity of the aqueous solution. Commer-cially available types contain up to 15 percent by weight. The fractions of alpha-gelatin and the oligomers thereof (9.5 x 104/105 to 106 D) are decisive for the solidity of the gel and they are conventionally between 10 and 40 percent by weight. Molecular weights below those of alpha-gelatin are designated as peptides and can amount to up to 80 percent by weight in conventional gelatin qualities (low Bloom value).
The sol/gel conversion behavior of gelatin, which depends on the molecular composition, is a function of temperature and concentration. The Bloom value is a con-ventional method for indicating the gelling capacity. Lowcommercial qualities start at 50 Bloom, types with a high Bloom value have around 300 Bloom.
Fractionated gelatin is a specific type of gelatin and is obtained from conventional gelatin by specific preparation processes, such as, for example, ultrafiltration. The composition can be varied, for example, by removing peptides (MW < 9.5 x 104 D) or by mixing individual fractions, such as, for example, alpha-chains, dimeric and trimeric chains or microgel.
Collagen in its native form is water-insoluble.
Nowadays, specific preparation processes allow soluble collagen types to be obtained.
Gelatin derivatives are chemically altered gelatins such as, for example, succinylated gelatin, and M:AL2740B 18.1.1993 - 10 -these are also known as plasma expanders.
Collagen hydrolysate is to be understood as a collagen or gelatin product which has no gelling capacity and which has been obtained by pressure hydrolysis or enzymatically. The molecular weight composition can range between a few hundred D up to below 9.5 x 104 D, depend-ing on the preparation. Collagen hydrolysates are soluble in cold water.
For external use, these substances of biogenic origin are not only distinguished by being well tolerated by the skin, they can also be incorporated particularly easily into ointments, creams and emulsions. ~ere, they display their specific property of acting somewhat as emulsifiers and emulsion stabilizers. Thus, for example, the use of substantial amounts of surfactants, which are skin irritants, can be reduced further, which contributes to their tolerance by the skin, a demand which must be met by pharmaceutical preparations, for example for the treatment of wounds, or by modern cosmetics. Gelatin and collagen hydrolysates are pharmaceutically recognized auxiliaries which are also preferably employed in the cosmetics industry.
The plant proteins and the hydrolysates thereof are novel products whose characteristics correspond largely to those of the collagen hydrolysates. They are preferably obtained from wheat and soybeans and have molecular weights of, for example, 200,000-300,000 D or 1000-10,000 D.
If plant proteins, plant protein hydrolysates or collagen hydrolysates (gelatins which are soluble in cold water) or gelatins whose molecular weight distribution has a maximum of some hundred D up to below 105 D are used, the lyophilized carrier material of the shaped articles according to the invention, surprisingly, forms a highly-porous network structure which is mechanically stable.
Elastin hydrolysates are obtained enzymatically from elastin and are composed of a single polypeptide chain with a high proportion of non-polar amino acids.
21Z82~;~
M:AL2740B 18.1.1993 - 11 -They can be used in lipophilic systems due to their hydrophobic properties. Elastin hydrolysates have a mole-cular weight of approximately 2000-3000 D and are strongly film-forming on the skin.
Rapid dissolution of the pellet formulae described is advantageous for instant uses such as, for example, instant teas, instant drinks (for example cough mixture), or instant creams without preservatives.
The recognized healing effect of fresh plant juices, for example Aloe vera juice, on internal use (health care) can be improved advantageously by the pellets according to the invention in the form of an instant preparation without preservatives. If, for example, a fresh plant juice is cryopelleted together with a rapidly dissolving matrix, storage-stable pellets are obtained, and these (which are, for example, in sachets) can be dissolved completely within a few seconds in water or fruit juices, milk or other beverages. In addition, complete instant beverages can be advantageously prepared according to the invention which are composed of fresh plant juice, a matrix composition of proteins of biogenic origin (for example collagen hydrolysates, wheat proteins) and natural skeleton builders, fruit juice extract, honey and other natural components. Components of the matrix such as, for example, gelatin, can mask unpleasant flavor, and glycerol and sorbitol can act as sweeteners which are gentle on the teeth.
If the pellets according to the invention are not in lyophilized form, but in solid or semi-solid form, they can be constructed advantageously of sol/gel-forming hydrophilic macromolecules, such as, for example, gelatin or fractionated gelatin, where the maximum of the molecu-lar weight distribution is above 105 D and the consist-ency is a direct function of the nature and concentrationof the addition of plasticizer.
Such pellets which contain plasticizers are outstAn~ingly suitable for converting essential oils into a solid, and therefore readily processable, form.
M:AL2740B 18.1.1993 - 12 -Semi-solid pellets, in particular, can be incor-porated into the matrix in such a manner that they melt or dissolve after application. Advantageous for external use in the field of both pharmaceutics and cosmetics is the gentleness on the skin of the matrix, which is com-posed of natural substances.
The following text describes the process for the preparation of the pellets according to the invention in greater detail.
More details in this contex' can be found in the parallel international (PCT) applications listed herein-below. These parallel PCT applications are:
WO93/137 57, WO 93/137 61, WO 93/137 53, and A
M:AL2740B 18.1.1993 - 13 -2 ~ 28242 If the extract is aqueous, alcoholic or aque-ous/alcoholic, the process according to the invention for the preparation of pellets cont~;n;ng plant extract(s) can ~e described by the following two process steps:
a) A skeleton builder of hydrophilic macromolecules from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant proteins, plant protein hydro-lysates and elastin hydrolysates, in solid or dis-solved form, is mixed with liquid, hydrophilic (aqueous, alcoholic or aqueous/alcoholic) plant extract.
b) The resulting mixture of skeleton builder and liquid hydrophilic plant extract is introduced dropwise into an intensely cold inert liquefied gas, thus making shaped articles.
A shaped article in the sense of the invention is to be understood as one selected from the group consisting of: powders, granules, pellets and essentially symmetric aggregates.
In the description of the invention, characteris-tics, preparation and use will be illustrated by way of preference with round pellets.
However, a person skilled in the art will also be able to employ other shaped articles from the group con-sisting of: powders, granules and essentially symmetric aggregates advantageously for the preparation of, in particular, pharmaceutical formulations.
If, for example, collagen hydrolysates or plant protein hydrolysates which are soluble in cold water are 212824~
M:AL2740~ 18.1.1993 - 14 -employed as skeleton builders, the process can be carried out in the absence of heat, i.e. in the mildest manner possible.
In an embodiment of the process described under a), a composition which is capable of forming drops, preferably composed of hydrophilic macromolecules as skeleton builders, in particular plant proteins, plant protein hydrolysates, collagen, gelatin, fractionated gelatin, collagen hydrolysates, elastin hydrolysates or gelatin derivatives and aqueous, alcoholic or aque-ous/alcoholic plant extract is prepared.
First, the desired skeleton builder, in particu-lar plant proteins, plant protein hydrolysates, collagen, gelatin, fractionated gelatin, gelatin derivatives or collagen hydrolysates, are dissolved either in the freshly obtained or in the already concentrated, liquid aqueous, alcoholic or aqueous/alcoholic plant extract, or the skeleton builder is already in dissolved form and as such mixed with the plant extract, type and quantity of the skeleton builder employed and, if appropriate, an addition of other auxiliaries depen~ing on the intended use of the pellets at a later point in time. The concen-tration of the carrier material can range, for example, from 0.5 to 60 % (w/w), preferably 0.5 to 30 % (based on the composition to be processed). If gelatin is employed, for example, then heat in a temperature range of 30~C to 45~C may have to be used in order to convert the gelatin into the sol form.
Furthermore, additives of the group consisting of: albumin, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dex-trins, maltodextrin, chitosan, alginates, cellulose derivatives, polyvinylpyrrolidone, dextran, sugars, glycine, lactose, mannitol, polyacrylic acid, methacrylic acid polymers, methacrylate polymers, and their mixtures may be added at a concentration of 1-50 %.
Further auxiliaries and carriers which are suitable for cosmetic, internal or pharmaceutical appli-cation, such as, for example, additional skeleton M:AL2740B 18.1.1993 - 15 -builders, which are described in greater detail further below, plasticizers such as, for example, glycerol or sorbitol, fillers such as, for example, lactose, disper-sants such as, for example, disodium phosphate, pH
regulators such as, for example, disodium citrate, emulsifiers such as, for example, lecithin, stabilizers such as, for example, ascorbic acid, cosolvents such as, for example, polyethylene glycol, natural colorants such as, for example, carotenoids, flavorings or masking flavors such as, for example, fruit juice concentrates, may be added to this basic matrix.
In a further process variant, 1-50 % (based on the composition to be processed) of plasticizers selected from the group consisting of: glycerol, propylene glycol, polyethylene glycols, triacetin, sorbitol, sorbitan mixtures, sorbitol solutions, glucose syrup and other polyols or sugar alcohols, and their mixtures may be added to the matrix.
Furthermore, it may be advantageous from the technological point of view to add other skeleton-build-ing substances to the formula in addition to the skeleton builder of hydrophilic macromolecules.
Additional skeleton builders which can be employed are: albumins, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, sugars, such as, for example, sucrose, glycine, lactose, PVP (polyvinylpyrrolidone), mannitol and combinations of the abovementioned sub-stances, but in particular mannitol.
In the case of plant extracts which are exceed-ingly thermolabile, a further embodiment of the invention surprisingly allows shaped articles to be provided which have the characteristics according to the invention and which have been prepared exclusively under cold condi-tions. In this procedure, a matrix of a hydrophilic macromolecule is used which is selected from the group consisting of: plant proteins, plant protein hydro-lysates, elastin hydrolysates, collagen hydrolysates, 212824~
M:AL2740B 18.1.1993 - 16 -gelatin which is soluble in cold water, gelatin deriva-tives; and mixtures of the abovementioned substances, whose molecular weight distribution has a maximum of below 105 D.
In an embodiment of the invention, additive substances may be selected from this group so as to adapt the physical or chemical properties of the matrix such as, for example, the viscosity, the mechanical strength or the dissolution characteristics of the polymeric skeleton to suit the intended use. Additions of dextrans, modified starches, sugars and, in particular, mannitol, allow, for example, pellets to be prepared according to the invention which dissolve in cold water spontaneously and completely.
Particularly suitable as additions of plasti-cizers are substances such as, for example, sorbitol, which are solid at room temperature after drying. Sur-prisingly, the matrix of such pellets forms a solid to semi-solid structure after lyophilization which, when brought into contact with aqueous medium or under physio-logical conditions, gives a bioadhesive and highly viscous characteristic in the sense of the invention.
If solids, for example dry extracts, are pro-cessed, then they can be either dissolved in the liquid matrix or suspended therein.
If liquid, lipophilic extracts (fatty or essen-tial oils) are processed, then they are emulsified in the liquid matrix. The surfactant properties of the matrix constituents, such as, for example, gelatin or collagen hydrolysate, can be utilized in an advantageous manner, so that, in many cases, the process can be carried out without an addition of an emulsifier. This is a consider-able advantage when the product is administered per-orally, but also when it is used on sensitive or injured skin or in cosmetics. Microemulsions mixed with the matrix may also be pelleted.
Fatty or essential oils which have been encapsu-lated by simple or complex coacervation and essential oils which have been encapsulated by spray-drying Zlz8z42 M:AL2740B 18.1.1993 - 17 -processes can be processed in the matrix according to the invention. It is also possible to produce microcapsules or coacervates in the dissolved matrix itself, and these microcapsules or coacervates together with the matrix are then made into pellets which contain microcapsules incorporated in the matrix. The same applies to nano-capsules.
For cosmetic purposes, it may furthermore be desired to add lipophilic components, such as, for example, phospholipids, to the matrices described so as to form liposomes.
In exceptional cases, the plant constituents themselves, in particular after concentration, may act as skeleton builders for the preparation of pellets accord-ing to the invention.
Of course, the mixtures according to the inven-tion are suitable for immediate decanting in liquid form by the process step as described under a) to form containers, such as, for example, moldings, soft-gelatin capsules and other suitable shells.
In an embodiment of the process step described under b), the matrix described is immersed into a bath in the range of -108~C to -210~C for rounding off (shaping) and shock frosting. The intensely cold and inert liquid used is preferably liquid nitrogen, which does not alter the constituents of the pellets. Round shaped articles (pellets) are formed in the intensely cold liquid, and these form a mechanically stable matrix after drying.
Shaping is effected by a suitable dosing system. Each discrete drop assumes the shape of a sphere, on the one hand as early as during the free descent, on the other hand in the immersion bath due to the gas layer which forms around it or the surface tension between system and gas, whereupon freezing is completed. It is precisely this rapid, but yet controllable freezing which fixes the given state of the system immediately, i.e. no plant extract constituents can diffuse into the surrounding medium, dissolved components can no longer crystallize, suspensions can no longer sediment, emulsions cannot 2128~
M:AL2740B 18.1.1993 - 18 -break, plant juice components which are sensitive to high temperatures or moisture are cryopreserved, the carrier skeleton cannot shrink and the like. The preparation process in which an inert liquid gas is used therefore results in no adverse effects or alteration of the product. Preservation of the desired characteristics is therefore particularly advantageous. Moreover, the process is carried out in the absence of solvents, does not pollute the environment and can be carried out under sterile conditions.
Suitable dosing systems are all devices which are capable of producing discrete, uniform drops whose size can be predetermined, for example pipette-like dripping devices, or suitable spray or atomizing nozzles equipped with dosing pumps.
Other devices which can be used for the process according to the invention are dosing devices equipped with single-substance nozzles which expel the material to be made into drops in a pulsed or intermittent fashion.
Another preferred embodiment of the process according to the invention employs the "Cryopel" process (based on DE-OS 37 11 169) developed by Messer Griesheim GmbH. With regard to the equipment used, scaling-up of the process according to the invention to an industrial scale is particularly simple in connection with an immer-sion frosting plant, the CryopelR plant. This plant, which can be operated with liquid nitrogen, is particu-larly distinguished by its economy. This plant is also suitable for working under sterile conditions. A continu-ous operation which requires little maintenance and cleaning allows an economical scaling-up of the process according to the invention to an industrial scale.
Fig. 1 shows a diagram of the CryopelR process developed by Messer Griesheim GmbH. From the heatable feeding device 1, the plant extract/matrix composition according to the invention is added dropwise through metered nozzles into the liquid nitrogen bath 3 at -196~C, where it is made into round pellets while simul-taneously being subjected to shock frosting. The frozen 2~Z8242 M:AL2740B 18.1.1993 --19 -product is discharged via device 5 by means of the con-tinuously operating conveyor belt 2. The liquid nitrogen is metered via inlet pipe 7, and the nitrogen gas formed escapes via pipe 6. The entire system is enclosed by the insulation 4.
Fig. 2 shows a diagram of a process in which the plant extract/matrix composition, which is either cold or heated at not more than 50~C, is added dropwise continu-ously via a controllable dosing pump 8 through the inlet pipe 9 and the heatable dropping nozzle 10 into the insulation trough 11, which contains liquid nitrogen 12.
The shock-frosted pellets are withdrawn batchwise. This device allows highly viscous compositions to be pro-cessed.
If the system to be processed is not sufficiently flowable or not sufficiently capable of forming drops, another 1-10 % by weight of water can be added, for example, or the processing temperature can be raised, or else pressure may be used for the dosing operation.
Analogously, a subatmospheric pressure is to be applied in the opposite case (if the viscosity of the system is too low). In this manner, a uniform formation as well as tearing off of the individual droplets are guaranteed.
The processing temperature can vary within wide limits, but should be below 50~C in the case of specific plant extracts, such as, for example, Aloe vera, to avoid thermal stress of the constituents.
Thus, a Cryopel dosing device allows compositions whose viscosity varies within a wide range, for example 1 x 10-3 to 12.5 Pa x s (Pascal seconds) to be dosed in a problem-free manner.
Other intensely cold liquids which are suitable for the process according to the invention may be, for example, liquid rare gases, such as argon.
Depending on the dosing system selected, a particle size uniformity of over 70 %, which can addi--tionally be improved by grading, may be achieved.
Fractions removed by grading can be converted back into the liquid state and repelleted, allowing the M:AL2740B 18.1.1993 - 20 -process to be carried out in a loss-free manner.
In an embodiment of the process step described, the pellets are dried, which results in two process variants.
Variant A:
The pellets, which have been frozen at -196~C, are introduced into a freeze-drying plant. The tempera-tures selected are from 15~C below the sublimation point of water at a pressure of 0.1 Pa to 103 Pa (0.001 to 1.03 mbar). The drying process, which proceeds in a conventional freeze-drying plant (condenser temperature -40~C) at -25~C and 33 Pa (0.33 mbar) in primary drying with sublimation of the matrix water, which has been frozen in amorphous form by means of shock-frosting, results in an end product having a highly porous network structure after secondary drying (desorption). In com-parison with conventionally freeze-dried goods, such pellets are particularly readily soluble and preferably suitable for the development of instant preparations.
Variant B:
The frozen pellets are defrosted and conven-tionally dried. This process can be carried out advan-tageously in vacuo (3000-5000 Pa (30-50 mbar)) to accelerate the drying process and to maintain low tem-peratures. Drying temperatures of up to 50~C may beselected, the temperature during the drying process in the pellet matrix not rising to above 30~C due to the evaporation enthalpy of the liquid.
In the case of conventionally dried pellets (variant B), sol/gel-forming substances required for the matrix are those which are capable of forming drops in sol form and which, after cryopelleting or defrosting, form a gel which is stable after drying. An addition of plasticizers has a beneficial effect on the formation of uniformly round shaped articles. Pellets which have been prepared in this manner are distinguished by economical preparation and can be employed both in the cosmetic and the pharmaceutical sector.
Compared with the prior art, the process M:AL2740B 18.1.1993 - 21 -according to the invention itself can be carried out, on the whole, with a low degree of maintenance and in an economical fashion.
The pellets according to the invention can be suitable for pharmaceutical purposes, but also peroral or cosmetic purposes.
The following are examples of pharmaceutical uses:
- Peroral unit dosage form (2-12 mm pellets) 10 - Pellets can also be filled directly into hard-gelatin capsules or sachets.
- As a basis for the preparation of tablets, coated tablets and the like.
- The pellets are outst~n~ingly suitable for direct tabletting. The high granulometric accuracy which can be achieved means that there are no dosing problems.
- Instant teas - In sachets, pellets can be offered for the prepara-tion of health-care drink solutions (instant preparation). If plant proteins, plant protein hydrolysates, collagen hydrolysates or gelatin are used whose molecular weight distribution has a maximum of some hundred D up to below 105 D, the pellets according to the invention dissolve in water at room temperature in the course of a few seconds.
Mixtures of a variety of plant extracts or with other active substances are also possible in this form.
The combination of Aloe vera with pharmaceuti-cally active substances, or active substances in dietet-ics (health care), can furthermore contribute to an improved tolerance of these substances, in particular when administered internally. For example, irritation of ZlZ8Z4~
M:AL2740B 18.1.1993 - 22 -the gastric mucosa by acetylsalicylic acid can be reduced effectively by the constituents of the Aloe vera juice, which have a protective action on the mucous membrane.
- Balneotherapeutic products, inhalants for dissolution in hot water - Preparation of ointments, creams, gels and the like for the treatment of wounds, for example in the case of burns and chemical burns and the like - Preparation of adhesive plasters and powders for use on wounds and the like - Pellets of active substance prepared under sterile conditions to be inserted into wounds The following are examples of cosmetic uses:
- Preparation of creams, instant creams, moisturizing emulsions, sun care products, products for use against solar dermatitis, shampoos, toothpastes, soaps, bath products, facial toners - Direct use of pellets for the preparation of facial masks, powders and the like - Use in cosmetics in the dissolved or semi-solid form - Use in cosmetics in combination with other active substances Due to the high variability of the formulae and the preparation processes described, the characteristics of the pellets according to the invention can be adjusted in a very simple manner to suit the intended aim.
A specific matrix formation allows direct use of pellets in solid and semi-solid form, dissolution being effected during application.
By varying the Bloom value of the gelatin X~Z8z42 M:AL2740B 18.1.1993 - 23 -employed according to the invention it is not only possible to control characteristics such as, for example, the dissolution rate of the pellets according to the invention, but also to adjust a desired viscosity of an aqueous solution of these pellets, again to suit the intended aim.
Such pellets have a series of advantages: the plant constituents remain unaltered in unpreserved form compared with liquid extracts or dry extracts prepared in the customary manner.
If plasticizers are added, they have an inimi-table appearance and are, moreover, very acceptable when ingested. Unpleasant flavor is already masked by the matrix components themselves.
They allow an alcohol-free drug preparation for plant extracts to be prepared or they can be employed as homoeopathic globuli. Compared with soft gelatin capsules, the active substance cannot leak. Volatile essential oils are formulated to give a solid preparation. In contrast to commercially available solutions and tinctures, their weight is low, and they can be swallowed easily as unit dosage forms.
The examples which follow are intended to illus-trate the invention in greater detail:
Example 1: Pellets as a bath preparation for a medicinal bath against rheumatic complaints (pharmaceutical appli-cation) 2.5 kg of gelatin, 150 Bloom 1.0 kg of glycerol 6.5 kg of water 375 g of juniper berry oil (essential oil) The gelatin is allowed to pre-swell in the glycerol/water mixture at room temperature for 30 minutes and is then dissolved at 60~C. After the essential oil of juniper berries has been added, the mixture is homogen-ized in an Ultra-Turrax, and the emulsion formed is added dropwise to liquid nitrogen at a temperature of -196~C
via the dosing device shown in Fig. 2. The pellets are dried in the air for 24 hours at 20~C and filled into 2~Z8242 M:AL2740B 18.1.1993 - 24 -containers.
g of these pellets when added to a bath dissolve completely in the warm water, releasing the essential oil. This gives a medicinal bath against rheumatic complaints.
Also advantageous against muscular pain is a mixture of 10 g of these pellets and 10 g of oil of rosemary pellets prepared in the same manner.
Melissa oil can be used to prepare a sedative bath.
To prepare pellets for inhalation, Oleum Pini Pumilionis is employed, and the pellets are dissolved in hot water before inhalation.
,Example 2: Vitamin E emulsion pellets, freeze-dried for use in a protective cream (cosmetic use) 0.15 kg of vitamin E obtained from wheatgerm oil 1.0 kg of collagen hydrolysate, molecular weight 13,000 - 18,000 g/mol 9 kg of water The collagen hydrolysate is dissolved in water at room temperature, and the liquid vitamin E is added while homogenizing in an Ultra-Turrax. The resulting emulsion is added dropwise to liquid nitrogen at -196~C via the dosing device as shown in Fig. 2 and shock-frosted in this manner. The water is then removed from the pellets by freeze-drying.
The dried pellets are incorporated into the following protective cream as "solid" vitamin E:
Lipid phase:
TegomulsR 90S 2.5 kg Soybean oil 5.0 kg Cocoa butter 1.5 kg Cetyl alcohol 1.5 kg Aqueous phase:
Distilled water 3.0 kg Active substance:
Vitamin E 30 g which correspond to 230 g of vitamin E emulsion pellets The pellets are emulsified with 1.8 1 of water.
Z~ z8z4z M:AL2740B 18.1.1993 --25 -The components of the lipid phase are melted at 65~C, and mixed with 1.2 kg of the water, which has been heated to the same temperature, with stirring, until a homogeneous mixture has formed. After the cream has S cooled to 30~C, the vitamin E/collagen hydrolysate emulsion is stirred in.
Example 3: Echinacea pellets, unit doage form Original echinacea tincture 2.16 kg Collagen hydrolysate, mean molecular weight 3000 g/mol 0.50 kg Distilled water 0.50 kg The collagen hydrolysate is dissolved in water at room temperature and the solution is mixed with the original tincture. The ethanol is removed from the ethanol/water mixture at 40~C under a vacuum of 5000 Pa (50 mbar) in a one-step vacuum evaporator.
The echinacea-contAining solution is added drop-wise to liquid nitrogen at -196~C via a dosing device as shown in Fig. 2, giving the pellets. These pellets are subsequently subjected to freeze-drying with a primary drying step at -50~C and 5 Pa (0.05 mbar) and a secondary drying step at 22~C.
After drying, the echinacea pellets have a diameter of 5 mm. 3xl pellets taken every day corresponds to the dosage as a prophylactic against common colds.
Example 4: Echinacea soft gelatin pellets:
Gelatin (140 Bloom) 250 g Glycerol 100 g Fresh echinacea juice (pressed-out juice) 5000.0 g The gelatin is allowed to swell for 30 minutes in the mixture of fresh plant juice and glycerol, this mixture is heated to 40~C, and such an amount of water that the composition is still flowable is removed under a vacuum at 5000 Pa (50 mbar) in a one-step evaporator at 40~C. The composition is cryopelleted as in Example 1 via a dosing device as shown in Fig. 2 and the pellets are-dried under the conditions indicated. The pellets, which have a diameter of 3.5 mm, are filled into a dosing dispenser. A unit dose of 5 pellets is withdrawn for use 2~28Z4~
M:AL2740B 18.1.1993 - 26 -as a prophylactic.
Example 5: Rutin suspension Gelatin 140 Bloom 200 g Glycerol 150 g 5 Distilled water 650 g Rutin 87.5 g A solution is prepared from gelatin, glycerol and water as described in Example 1, and the rutin is sus-pended in powder form. Pelleting and drying is effected as shown in Example 1. 5 pellets of diameter 3.5 mm contain a dose of 50 mg of rutin.
Example 6: Aloe vera juice 150 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 3000 g of Aloe vera juice, solids concentration 0.6 %
(w/w) Freshly obtained fillets of Aloe vera leaves are homogenized, and the product is purified and filtered.
The collagen hydrolysate is dissolved, with stirring, in the resulting, cooled Aloe vera juice. This solution is then used for forming pellets at -196~C in an immersion bath cont~ining liquid nitrogen, using the CryopelR
feeding device.
The shock-frosted, round shaped articles are dried in a freeze-drying plant where the primary drying step is carried out at -50~C and 5 Pa (0.05 mbar) and the secondary drying step at 22~C.
This gives pellets of diameter 4 mm and an Aloe vera content of 10.7 % (w/w, dry matter). Grading shows a granulometric accuracy of 78 %.
The pellets dissolve completely in water at room temperature in the course of 20 seconds.
, Example 7:
100 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 50 g of mannitol 50 g of wheat protein hydrolysate, molecular weight < 5000 g/mol 2000 g of Aloe vera juice, solids concentration 0.6 %
Z~ 824z M:AL2740B 18.1.1993 - 27 -The collagen hydrolysate, the wheat protein hydrolysate and the mannitol are dissolved in the cold Aloe vera juice, which has been processed as shown in Example 6, and pellets are prepared as shown in Example 6. This gives pellets of diameter 3 mm and an Aloe vera solids content of 5.7 % (w/w). Dissolved in orange juice or passion fruit juice, these pellets can be used as a drink solution.
~Example 8:
200 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 4000 g of Aloe vera juice, 10 x concentrate The Aloe vera juice obtained in Example 6 is brought to a concentration of 10 x at 40~C under a vacuum of 5000 Pa (50 mbar) by means of a one-step vacuum evaporator. The collagen hydrolysate is dissolved in the juice, and lyophilized pellets are prepared after short-term pasteurization. Round shaped articles of diameter 4.5 mm and an Aloe vera solids content of 54.5 % (w/w) are obtained.
The pellets dissolve in water at room temperature in the course of 40 seconds.
5 g of these pellets dissolved in 100 ml of sterile water give an effective instant formula against solar dermatitis.
Example 9:
Incorporation of the pellets according to the invention into a night cream a) Preparation of the pellets 300 g of collagen hydrolysate, mean molecular weight:
13,000-18,000 g/mol 4000 g of Aloe vera juice, solids concentration 0.6 %
Lyophilized pellets with an Aloe vera solids content of 7.4 % (w/w) are prepared as described in Example 6.
b) Night cream formula Lipid phase:
200 g of Tegomuls 90S
750 g of avocado oil 2~28~4;~
M:AL2740B 18.1.1993 - 28 -Aqueou~ phase:
200 g of native collagen (3 % solution, molecular weight 300,000 g/mol) 30 g of elastin 32 g of Aloe vera pellets as described under a) 3000 g of freshly distilled water The lipid phase is melted at 70~C. The water is also heated to 70~C, and the elastin is dissolved there-in. The resulting aqueous solution is homogenized in the lipid phase. The cream base is cooled to 35~C. The Aloe vera pellets are dissolved in the cold collagen solution and dispersed homogeneously in the cream base.
Example 10:
400 g of commercially available gelatin (170 Bloom) 300 g of glycerol (85 %) 1300 g of Aloe vera juice, solids concentration 0.5 %
(w/w) The gelatin powder is added to the freshly obtained and homogenized Aloe vera juice and allowed to pre-swell for approximately 45 minutes. The mixture is subsequently dissolved completely at 40~C, and the glycerol is admixed to give a homogeneous mixture.
The solution, which has a temperature of 40~C, is subsequently dosed into the immersion bath cont~in;ng liquid nitrogen via the pump in the plant shown in Fig. 2, and pellets are made. The deep-frozen, round shaped articles are defrosted and dried at a rising temperature at between 25~C and 40~C. The pellets have a residual moisture content of 10 % and are storage-stable.
The pellets which have been prepared in this manner can be incorporated into a commercially available hydrogel (for example polyacrylate gel). The pellets swell in the hydrogel after 10 to 15 minutes up to twice their original size and form gel-like, readily meltable shaped articles which dissolve after application to the skin.
Alternatively, the pellets can also be added directly to the hydrogel without drying and without intermediate storage.
The invention furthermore relates to a mild process for the preparation of such pellets or true spheres and to their pharmaceutical, peroral or cosmetic application.
The plant extract which is preferably employed is Aloe vera juice.
The plant extracts in the sen~e of the present invention are juices from fresh plants obtained directly from the plant, pressed-out juices from fresh plants, either in the original concentration or in concentrated form, filtered and unfiltered, hydrophilic extracts (aqueous or alcoholic extracts, for example ethanol extracts or 1,2-propylene glycol extracts) such as, for example, original tinctures in homeopathy, fluid extracts, macerates, lipophilic extracts (such as, for example, garlic oil), essential oils, complete extracts or specifically stAn~Ardized extracts (for example stAn~rdized to a specific flavone glycoside content), essential oil extracts, individually isolated plant constituents (such as, for example, rutin), synthetic analogs (such as, for example, perfume oils, camphor, thymol, vanillin) and derivatized plant constituents (such as, for example, aglycones).
In individual cases, it is also possible to use dry extracts or the redissolved extract from a dry extract in a suitable solvent, or decoctions prepared therefrom. Pulverized drug constituents (for example leaves, roots, herbaceous parts) can also be processed.
Being natural substances, plant extracts are frequently sensitive to external factors such as light, M:AL2740B 18.1.1993 - 2 -oxidation by atmospheric oxygen, heat, p~ effects in solutions, or microbial contamination. In many plant-derived active substances, it is known that only the fresh juice obtained originally from the plant or parts thereof (for example Echinacea pressed-out juice or Aloe vera juice) have optimum activity. Each means of preser-vation, such as drying by heat, chemical preservation, heat treatment for preservation purposes and the like adversely affect the delicate plant constituents with regard to their chemical structure and thus their activ-ity. In most cases, preservation against microbial cont~mination is unavoidable when using fresh plant juices so as to achieve at least limited shelf life.
In addition, the dry matter content of such fresh plant juices is very low, and a large amount of water is being transported or stored.
Lipophilic plant extracts which are sensitive to oxidation, such as vitamin E or garlic oil, are difficult to store in unaltered form and usually have to be pro-cessed at once.
Essential oils are volatile and difficult tohandle in the form of liquids.
Aloe vera (Aloe barbadensis Miller; synonyms:
Aloe vera Tournefort et Linné, Aloe vulgaris Lamarck) has been used for a long time in traditional medicine of those regions in which this plant, which belongs to the family of the Liliaceae grows wild.
If used externally, the gel-like plant juice has, for example, a beneficial effect on wound healing, acts as an antibiotic or has a softening effect on the skin.
Aloe vera juice can be administered internally in the treatment of gastric diseases and disorders of the gastrointestinal tract. Anti-inflammatory properties have also been reported.
These original findings have led to large planta-tions of Aloe vera having been established in Central America, South America and parts of North America. The juice in the leaves is obtained at the site itself in a laborious process and subsequently concentrated under the Z~28242 M:AL2740B 18.1.1993 - 3 -mildest possible conditions. The concentration of plant constituents in the freshly obtained juice is between 0.3 and approximately 1 %. Fresh Aloe vera fillets, aqueous concentrates or spray- or freeze-dried goods are all commercially available. The differences in quality of commercially available products are considerable with regard to stability and composition and depend largely on the preparation technology employed.
Aqueous concentrates or the juice from the leaves are currently being used successfully in dermatoses (for example burns by the action of heat, W rays or X-rays), chemical burns, wounds, gastric diseases or parodontosis.
It appears that the pharmacological effect is only to be attributed to the total of all constituents. A demonstra-tion of the effect of individual components is currentlybeing investigated extensively.
However, since no undesired side-effects of Aloe vera juice are known, this natural product has been offered for sale for many years in creams, moisturizing emulsions, sun care products or for internal use.
The shelf life, or stability of storage, of the aqueous plant gel causes substantial difficulties.
Despite preservation, the liquid product is unstable to the action of heat and pH, sensitive to oxygen and, moreover, highly susceptible to microbial contamination.
The transport of fresh Aloe vera juice is diffi-cult and costly due to the high liquid volume - 90-99 %
of water are transported - and the abovementioned insta-bility phenomena. Moreover, the juice must be cooled until it is used in production. The preparation methods which involve the process steps initial washing of the leaves, obtA;ning the fillets, homogenization, purifica-tion and filtration, concentration and drying, can result in changes in the constituents and bacterial contamina-tion of the end product in question if the technologyused is unsuitable.
Aloe vera powders obtained by spray- or freeze-drying are only sparingly redissolvable in cold water since they lack wettability and because there is a danger ZlZ8Z42 M:AL2740B 18.1.1993 - 4 -of lump formation. Moreover, freeze-dried products are hygroscopic and easily form lumps when stored inade-quately. Commercially available products which are readily dissolvable in water are frequently treated with surfactants, which are undesired in cosmetics.
It is therefore an object of the invention to provide unpreserved, storage-stable, concentrated, solid or semi-solid forms of plant extracts, in particular of Aloe vera juice, which can be redissolved without problem and whose pharmacological and cosmetic properties remain unaltered compared with the native plant juice.
This object is achieved according to the inven-tion by pellets contA;ning plant extract, which comprise a dispersion of the plant extract in a matrix contA;n;ng predominantly a skeleton builder of a hydrophilic macromolecule.
The following are employed as hydrophilic macromolecules: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant pro-teins, plant protein hydrolysates, elastin hydrolysates;and mixtures of the abovementioned substances.
This object is furthermore achieved by a process for the preparation of pellets contAining plant extract(s), which comprises mixing or emulsifying the skeleton builder in solid or dissolved form with liquid plant extract, or dissolving or suspending solid extracts in a solution of the skeleton builder and making the product into shaped articles. If required, the shaped articles can be dried.
The only aspect that requires attention is that matrix systems and active substance must not be incompatible.
In particular, the present invention provides shaped articles contAining a plant extract, which com-prise a dispersion of the plant extract in a matrix composed predominantly of a skeleton builder of hydro-philic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, elastin hydrolysates, plant proteins, plant protein hydrolysates; and their Z~Z8~4Z
M:AL2740B 18.1.1993 - 5 -mixtures.
The present invention furthermore provides aprocess for the preparation of shaped articles cont~ining plant extract, wherein a) a skeleton builder of hydrophilic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolys-ates, gelatin derivatives, plant proteins, plant protein hydrolysates, elastin hydrolysates; and their mixtures, .
is mixed with plant extracts selected from the group consisting of:
hydrophilic liquid plant extracts, aqueous extracts, alcoholic extracts; and their mixtures; and b) the resulting mixture of skeleton builder and plant extract is added dropwise to an intensely cold inert liquid, thus making it into shaped articles.
Preferred embodiments of the invention are described and claimed in the subclaims.
The following are examples of plant extracts or of extracts or individual substances obtained therefrom:
Flavonoids and their aglycones:
rutin, quercetin, diosmin, hyperoside, (neo)hesperidin, hesperitin, Ginkgo biloba (for example ginkgo flavone glycosides), Crataegus extract (for example oligomeric procyanidines), buckwheat (for example rutin), Sophora japonica (for example rutin), birch leaves (for example quercetin glycosides, hyperoside and rutin), elderflower (for example rutin), lime flower (for example essential oil contAining quercetin and farnesol), St John's wort oil (for example olive oil extract), calendula, arnica (for example oily extracts of the flowers with essential oil, polar extracts with flavonoids), balm (for example flavones, essential oil), M:AL2740B 18.1.1993 - 6 - 2128~42 Essential oils:
sage (for example essential oil cont~ining thymol), aniseed (for example essential oil cont~ining trans-anethol), oil of cloves (for example essential oil cont~;n;ng eugenol), camomile (for example chamazulene, alpha-bisabolol), myrtol: (limonene, alpha-pinene, cineol), oil of peppermint (for example oil cont~;n;ng menthol), caraway (for example oil cont~;ning carvone), dwarf pine oil (for example oil contAin;ng alpha-pinene), juniper, rosemary, eucalyptus oil, lavender, fir leaf oil, bergamot oil, citrus oil, balm, marjoram, thyme, basil (stomachic tonics or condiments), fennel Fatty oils:
for example wheatgerm oil and vitamin E isolated there-from, oil of evening pri~rose (for example gamma-linolenic acid), plant lecithins (for example soybean lecithin), sphingolipids/ceramides isolated from plants Immunostimulants:
Echinacea purpurea (for example alcoholic extracts, fresh plant juice, pressed-out juice), Eleutherococcus senti-cosus Alkaloids:
rauwolfia (for example prajmalin), periwinkle (for example vincamin) Other phytopharmaceuticals:
aloe, horse chestnut (for example aescin), garlic (for example garlic oil), pineapple (for example bromelains), ginseng (for example ginsenosides), Our Lady's thistle fruit (for example extract st~n~rdized with regard to silymarin), box holly root (for example ruscogenin),valerian (for example valepotriates, Tct. Valerianae), kava kava (for example kavalactones), hop flowers (for example hop bitters), Extr. Passiflorae, gentian (for example ethanolic extract), anthraquinone-cont~ining drug extracts, for example aloin-cont~ining Aloe vera juice, pollen extract, extracts from algae, licorice extracts, palm extract, galphi~ia (for example original tincture), mistletoe (for example aqueous ethanolic extract), phyto-sterols (for example beta-sitosterin), verbascum (for M:AL2740B 18.1.1993 --7 - 2128242 example aqueous-alcoholic extract), drosera (for example vinum liquorosum extract), sea buckthorn fruit (for example juice obtained therefrom or sea buckthorn oil), marshmallow root, primula root extract, fresh plant extracts of mallow, comfrey, ivy, horsetail, yarrow, ribwort (for example pressed-out juice), stinging nettle, greater celandine, parsley.
Plant extracts of Norolaena lobata, Tagetes lucida, Tecoma siems, Momordica charantia.
As a rule, the plant extract is generally selected from the group consisting of: solid plant extracts, liquid plant extracts, hydrophilic plant extracts, lipophilic plant extracts, individual plant constituents; and mixtures of these.
In general, the literature mentions Aloe vera juice, Aloe vera gel and Aloe vera extracts. The term "Aloe vera juice" used in the sense of the invention is to be understood as meaning, in general, the native juice obtained directly from the leaf, the filtered or purified juice, the juice which has been concentrated under mild conditions and also the redissolved juice made of a dry extract. For internal use, it is also possible to use the whole leaf, leaf constituents and flowers in homogenized form. Alternatively, individual constituents may be suitable for specific uses.
The pellets according to the invention are spherical, uniform shaped articles whose diameters have a customary range of 0.8 - 2 mm. Moreover, sizes of 0.2 -0.8 and 2 - 12 mm can be prepared according to the invention. Pellets with a diameter of over 2 mm are termed true spheres in the present invention, and they are suitable as single unit dosage form.
Surprisingly, the pellets display a great mechanical strength combined with a low degree of abrasion (friability). They are storage-stable, can be metered readily and are obtained as a free-flowing material due to the specific preparation process. They can contain plant extract(s) at concentrations of 0.1 - 98 % (percent by weight), preferably 0.1 - 60 %, 21Z~42 M:AL2740B 18.1.1993 - 8 -calculated as solids.
Surprisingly, neither the nature nor the composition of the constituents of the native plant con-stituents are altered by the pellets according to the invention. As a cold process, the process according to the invention is a very mild form of processing. The pellets cont~;ning plant extract(s) can exist in the form of a lyophilisate or in the form of solid or gel-like pellets, depen~;ng on the preparation.
Preservatives or a heat treatment for preserva-tion purposes can be dispensed with by conversion into pellet form, using the matrix systems according to the invention.
A pelleted fresh plant juice is storage-stable.
If, for example, solvent extraction is required for stability reasons, this can be dispensed with.
Furthermore, liquids can be converted into the solid form (essential oils or fatty oils). This improves storage stability, transportability and the handling quality of such substances.
The pellets, which have been dried conventionally according to the invention, with or without addition of plasticizers, can be recognized easily by their characteristic, typical appearance: they are transparent or opalescent.
The product according to the invention can be employed directly for pharmaceutical purposes, for internal use or for cosmetic purposes.
For pharmaceutical purposes, the pellets, as multiple unit dosage forms, can be filled into sachets or hard gelatin capsules in the form of granules, further-more in the form of beverage granules for the preparation of drink solutions (for example instant teas), and they can be packaged as single unit dosage forms, i.e. single unit dose pellets for example filled into suitable containers, blister packs or dosing dispensers for withdrawing them singly. A further single unit form is represented by rapidly dissolving tablets made by compressing freeze-dried pellets.
21Z8;~
M:AL2740B 18.1.1993 - 9 -For cosmetic uses, it is particularly advantage-ous according to the invention to use plant proteins or hydrolysates thereof, soluble collagen, gelatin, collagen hydrolysates, elastin or elastin hydrolysates as carrier materials of the shaped articles.
Gelatin is a scleroprotein obtained from collagen-cont~;n;ng material, and its properties vary depending on the preparation process. It is composed essentially of four molecular weight fractions which have an effect on physicochemical properties as a function of the molecular weight and the percentage by weight. For example, the more microgel (107 to 108 D) present, the higher the viscosity of the aqueous solution. Commer-cially available types contain up to 15 percent by weight. The fractions of alpha-gelatin and the oligomers thereof (9.5 x 104/105 to 106 D) are decisive for the solidity of the gel and they are conventionally between 10 and 40 percent by weight. Molecular weights below those of alpha-gelatin are designated as peptides and can amount to up to 80 percent by weight in conventional gelatin qualities (low Bloom value).
The sol/gel conversion behavior of gelatin, which depends on the molecular composition, is a function of temperature and concentration. The Bloom value is a con-ventional method for indicating the gelling capacity. Lowcommercial qualities start at 50 Bloom, types with a high Bloom value have around 300 Bloom.
Fractionated gelatin is a specific type of gelatin and is obtained from conventional gelatin by specific preparation processes, such as, for example, ultrafiltration. The composition can be varied, for example, by removing peptides (MW < 9.5 x 104 D) or by mixing individual fractions, such as, for example, alpha-chains, dimeric and trimeric chains or microgel.
Collagen in its native form is water-insoluble.
Nowadays, specific preparation processes allow soluble collagen types to be obtained.
Gelatin derivatives are chemically altered gelatins such as, for example, succinylated gelatin, and M:AL2740B 18.1.1993 - 10 -these are also known as plasma expanders.
Collagen hydrolysate is to be understood as a collagen or gelatin product which has no gelling capacity and which has been obtained by pressure hydrolysis or enzymatically. The molecular weight composition can range between a few hundred D up to below 9.5 x 104 D, depend-ing on the preparation. Collagen hydrolysates are soluble in cold water.
For external use, these substances of biogenic origin are not only distinguished by being well tolerated by the skin, they can also be incorporated particularly easily into ointments, creams and emulsions. ~ere, they display their specific property of acting somewhat as emulsifiers and emulsion stabilizers. Thus, for example, the use of substantial amounts of surfactants, which are skin irritants, can be reduced further, which contributes to their tolerance by the skin, a demand which must be met by pharmaceutical preparations, for example for the treatment of wounds, or by modern cosmetics. Gelatin and collagen hydrolysates are pharmaceutically recognized auxiliaries which are also preferably employed in the cosmetics industry.
The plant proteins and the hydrolysates thereof are novel products whose characteristics correspond largely to those of the collagen hydrolysates. They are preferably obtained from wheat and soybeans and have molecular weights of, for example, 200,000-300,000 D or 1000-10,000 D.
If plant proteins, plant protein hydrolysates or collagen hydrolysates (gelatins which are soluble in cold water) or gelatins whose molecular weight distribution has a maximum of some hundred D up to below 105 D are used, the lyophilized carrier material of the shaped articles according to the invention, surprisingly, forms a highly-porous network structure which is mechanically stable.
Elastin hydrolysates are obtained enzymatically from elastin and are composed of a single polypeptide chain with a high proportion of non-polar amino acids.
21Z82~;~
M:AL2740B 18.1.1993 - 11 -They can be used in lipophilic systems due to their hydrophobic properties. Elastin hydrolysates have a mole-cular weight of approximately 2000-3000 D and are strongly film-forming on the skin.
Rapid dissolution of the pellet formulae described is advantageous for instant uses such as, for example, instant teas, instant drinks (for example cough mixture), or instant creams without preservatives.
The recognized healing effect of fresh plant juices, for example Aloe vera juice, on internal use (health care) can be improved advantageously by the pellets according to the invention in the form of an instant preparation without preservatives. If, for example, a fresh plant juice is cryopelleted together with a rapidly dissolving matrix, storage-stable pellets are obtained, and these (which are, for example, in sachets) can be dissolved completely within a few seconds in water or fruit juices, milk or other beverages. In addition, complete instant beverages can be advantageously prepared according to the invention which are composed of fresh plant juice, a matrix composition of proteins of biogenic origin (for example collagen hydrolysates, wheat proteins) and natural skeleton builders, fruit juice extract, honey and other natural components. Components of the matrix such as, for example, gelatin, can mask unpleasant flavor, and glycerol and sorbitol can act as sweeteners which are gentle on the teeth.
If the pellets according to the invention are not in lyophilized form, but in solid or semi-solid form, they can be constructed advantageously of sol/gel-forming hydrophilic macromolecules, such as, for example, gelatin or fractionated gelatin, where the maximum of the molecu-lar weight distribution is above 105 D and the consist-ency is a direct function of the nature and concentrationof the addition of plasticizer.
Such pellets which contain plasticizers are outstAn~ingly suitable for converting essential oils into a solid, and therefore readily processable, form.
M:AL2740B 18.1.1993 - 12 -Semi-solid pellets, in particular, can be incor-porated into the matrix in such a manner that they melt or dissolve after application. Advantageous for external use in the field of both pharmaceutics and cosmetics is the gentleness on the skin of the matrix, which is com-posed of natural substances.
The following text describes the process for the preparation of the pellets according to the invention in greater detail.
More details in this contex' can be found in the parallel international (PCT) applications listed herein-below. These parallel PCT applications are:
WO93/137 57, WO 93/137 61, WO 93/137 53, and A
M:AL2740B 18.1.1993 - 13 -2 ~ 28242 If the extract is aqueous, alcoholic or aque-ous/alcoholic, the process according to the invention for the preparation of pellets cont~;n;ng plant extract(s) can ~e described by the following two process steps:
a) A skeleton builder of hydrophilic macromolecules from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant proteins, plant protein hydro-lysates and elastin hydrolysates, in solid or dis-solved form, is mixed with liquid, hydrophilic (aqueous, alcoholic or aqueous/alcoholic) plant extract.
b) The resulting mixture of skeleton builder and liquid hydrophilic plant extract is introduced dropwise into an intensely cold inert liquefied gas, thus making shaped articles.
A shaped article in the sense of the invention is to be understood as one selected from the group consisting of: powders, granules, pellets and essentially symmetric aggregates.
In the description of the invention, characteris-tics, preparation and use will be illustrated by way of preference with round pellets.
However, a person skilled in the art will also be able to employ other shaped articles from the group con-sisting of: powders, granules and essentially symmetric aggregates advantageously for the preparation of, in particular, pharmaceutical formulations.
If, for example, collagen hydrolysates or plant protein hydrolysates which are soluble in cold water are 212824~
M:AL2740~ 18.1.1993 - 14 -employed as skeleton builders, the process can be carried out in the absence of heat, i.e. in the mildest manner possible.
In an embodiment of the process described under a), a composition which is capable of forming drops, preferably composed of hydrophilic macromolecules as skeleton builders, in particular plant proteins, plant protein hydrolysates, collagen, gelatin, fractionated gelatin, collagen hydrolysates, elastin hydrolysates or gelatin derivatives and aqueous, alcoholic or aque-ous/alcoholic plant extract is prepared.
First, the desired skeleton builder, in particu-lar plant proteins, plant protein hydrolysates, collagen, gelatin, fractionated gelatin, gelatin derivatives or collagen hydrolysates, are dissolved either in the freshly obtained or in the already concentrated, liquid aqueous, alcoholic or aqueous/alcoholic plant extract, or the skeleton builder is already in dissolved form and as such mixed with the plant extract, type and quantity of the skeleton builder employed and, if appropriate, an addition of other auxiliaries depen~ing on the intended use of the pellets at a later point in time. The concen-tration of the carrier material can range, for example, from 0.5 to 60 % (w/w), preferably 0.5 to 30 % (based on the composition to be processed). If gelatin is employed, for example, then heat in a temperature range of 30~C to 45~C may have to be used in order to convert the gelatin into the sol form.
Furthermore, additives of the group consisting of: albumin, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dex-trins, maltodextrin, chitosan, alginates, cellulose derivatives, polyvinylpyrrolidone, dextran, sugars, glycine, lactose, mannitol, polyacrylic acid, methacrylic acid polymers, methacrylate polymers, and their mixtures may be added at a concentration of 1-50 %.
Further auxiliaries and carriers which are suitable for cosmetic, internal or pharmaceutical appli-cation, such as, for example, additional skeleton M:AL2740B 18.1.1993 - 15 -builders, which are described in greater detail further below, plasticizers such as, for example, glycerol or sorbitol, fillers such as, for example, lactose, disper-sants such as, for example, disodium phosphate, pH
regulators such as, for example, disodium citrate, emulsifiers such as, for example, lecithin, stabilizers such as, for example, ascorbic acid, cosolvents such as, for example, polyethylene glycol, natural colorants such as, for example, carotenoids, flavorings or masking flavors such as, for example, fruit juice concentrates, may be added to this basic matrix.
In a further process variant, 1-50 % (based on the composition to be processed) of plasticizers selected from the group consisting of: glycerol, propylene glycol, polyethylene glycols, triacetin, sorbitol, sorbitan mixtures, sorbitol solutions, glucose syrup and other polyols or sugar alcohols, and their mixtures may be added to the matrix.
Furthermore, it may be advantageous from the technological point of view to add other skeleton-build-ing substances to the formula in addition to the skeleton builder of hydrophilic macromolecules.
Additional skeleton builders which can be employed are: albumins, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, sugars, such as, for example, sucrose, glycine, lactose, PVP (polyvinylpyrrolidone), mannitol and combinations of the abovementioned sub-stances, but in particular mannitol.
In the case of plant extracts which are exceed-ingly thermolabile, a further embodiment of the invention surprisingly allows shaped articles to be provided which have the characteristics according to the invention and which have been prepared exclusively under cold condi-tions. In this procedure, a matrix of a hydrophilic macromolecule is used which is selected from the group consisting of: plant proteins, plant protein hydro-lysates, elastin hydrolysates, collagen hydrolysates, 212824~
M:AL2740B 18.1.1993 - 16 -gelatin which is soluble in cold water, gelatin deriva-tives; and mixtures of the abovementioned substances, whose molecular weight distribution has a maximum of below 105 D.
In an embodiment of the invention, additive substances may be selected from this group so as to adapt the physical or chemical properties of the matrix such as, for example, the viscosity, the mechanical strength or the dissolution characteristics of the polymeric skeleton to suit the intended use. Additions of dextrans, modified starches, sugars and, in particular, mannitol, allow, for example, pellets to be prepared according to the invention which dissolve in cold water spontaneously and completely.
Particularly suitable as additions of plasti-cizers are substances such as, for example, sorbitol, which are solid at room temperature after drying. Sur-prisingly, the matrix of such pellets forms a solid to semi-solid structure after lyophilization which, when brought into contact with aqueous medium or under physio-logical conditions, gives a bioadhesive and highly viscous characteristic in the sense of the invention.
If solids, for example dry extracts, are pro-cessed, then they can be either dissolved in the liquid matrix or suspended therein.
If liquid, lipophilic extracts (fatty or essen-tial oils) are processed, then they are emulsified in the liquid matrix. The surfactant properties of the matrix constituents, such as, for example, gelatin or collagen hydrolysate, can be utilized in an advantageous manner, so that, in many cases, the process can be carried out without an addition of an emulsifier. This is a consider-able advantage when the product is administered per-orally, but also when it is used on sensitive or injured skin or in cosmetics. Microemulsions mixed with the matrix may also be pelleted.
Fatty or essential oils which have been encapsu-lated by simple or complex coacervation and essential oils which have been encapsulated by spray-drying Zlz8z42 M:AL2740B 18.1.1993 - 17 -processes can be processed in the matrix according to the invention. It is also possible to produce microcapsules or coacervates in the dissolved matrix itself, and these microcapsules or coacervates together with the matrix are then made into pellets which contain microcapsules incorporated in the matrix. The same applies to nano-capsules.
For cosmetic purposes, it may furthermore be desired to add lipophilic components, such as, for example, phospholipids, to the matrices described so as to form liposomes.
In exceptional cases, the plant constituents themselves, in particular after concentration, may act as skeleton builders for the preparation of pellets accord-ing to the invention.
Of course, the mixtures according to the inven-tion are suitable for immediate decanting in liquid form by the process step as described under a) to form containers, such as, for example, moldings, soft-gelatin capsules and other suitable shells.
In an embodiment of the process step described under b), the matrix described is immersed into a bath in the range of -108~C to -210~C for rounding off (shaping) and shock frosting. The intensely cold and inert liquid used is preferably liquid nitrogen, which does not alter the constituents of the pellets. Round shaped articles (pellets) are formed in the intensely cold liquid, and these form a mechanically stable matrix after drying.
Shaping is effected by a suitable dosing system. Each discrete drop assumes the shape of a sphere, on the one hand as early as during the free descent, on the other hand in the immersion bath due to the gas layer which forms around it or the surface tension between system and gas, whereupon freezing is completed. It is precisely this rapid, but yet controllable freezing which fixes the given state of the system immediately, i.e. no plant extract constituents can diffuse into the surrounding medium, dissolved components can no longer crystallize, suspensions can no longer sediment, emulsions cannot 2128~
M:AL2740B 18.1.1993 - 18 -break, plant juice components which are sensitive to high temperatures or moisture are cryopreserved, the carrier skeleton cannot shrink and the like. The preparation process in which an inert liquid gas is used therefore results in no adverse effects or alteration of the product. Preservation of the desired characteristics is therefore particularly advantageous. Moreover, the process is carried out in the absence of solvents, does not pollute the environment and can be carried out under sterile conditions.
Suitable dosing systems are all devices which are capable of producing discrete, uniform drops whose size can be predetermined, for example pipette-like dripping devices, or suitable spray or atomizing nozzles equipped with dosing pumps.
Other devices which can be used for the process according to the invention are dosing devices equipped with single-substance nozzles which expel the material to be made into drops in a pulsed or intermittent fashion.
Another preferred embodiment of the process according to the invention employs the "Cryopel" process (based on DE-OS 37 11 169) developed by Messer Griesheim GmbH. With regard to the equipment used, scaling-up of the process according to the invention to an industrial scale is particularly simple in connection with an immer-sion frosting plant, the CryopelR plant. This plant, which can be operated with liquid nitrogen, is particu-larly distinguished by its economy. This plant is also suitable for working under sterile conditions. A continu-ous operation which requires little maintenance and cleaning allows an economical scaling-up of the process according to the invention to an industrial scale.
Fig. 1 shows a diagram of the CryopelR process developed by Messer Griesheim GmbH. From the heatable feeding device 1, the plant extract/matrix composition according to the invention is added dropwise through metered nozzles into the liquid nitrogen bath 3 at -196~C, where it is made into round pellets while simul-taneously being subjected to shock frosting. The frozen 2~Z8242 M:AL2740B 18.1.1993 --19 -product is discharged via device 5 by means of the con-tinuously operating conveyor belt 2. The liquid nitrogen is metered via inlet pipe 7, and the nitrogen gas formed escapes via pipe 6. The entire system is enclosed by the insulation 4.
Fig. 2 shows a diagram of a process in which the plant extract/matrix composition, which is either cold or heated at not more than 50~C, is added dropwise continu-ously via a controllable dosing pump 8 through the inlet pipe 9 and the heatable dropping nozzle 10 into the insulation trough 11, which contains liquid nitrogen 12.
The shock-frosted pellets are withdrawn batchwise. This device allows highly viscous compositions to be pro-cessed.
If the system to be processed is not sufficiently flowable or not sufficiently capable of forming drops, another 1-10 % by weight of water can be added, for example, or the processing temperature can be raised, or else pressure may be used for the dosing operation.
Analogously, a subatmospheric pressure is to be applied in the opposite case (if the viscosity of the system is too low). In this manner, a uniform formation as well as tearing off of the individual droplets are guaranteed.
The processing temperature can vary within wide limits, but should be below 50~C in the case of specific plant extracts, such as, for example, Aloe vera, to avoid thermal stress of the constituents.
Thus, a Cryopel dosing device allows compositions whose viscosity varies within a wide range, for example 1 x 10-3 to 12.5 Pa x s (Pascal seconds) to be dosed in a problem-free manner.
Other intensely cold liquids which are suitable for the process according to the invention may be, for example, liquid rare gases, such as argon.
Depending on the dosing system selected, a particle size uniformity of over 70 %, which can addi--tionally be improved by grading, may be achieved.
Fractions removed by grading can be converted back into the liquid state and repelleted, allowing the M:AL2740B 18.1.1993 - 20 -process to be carried out in a loss-free manner.
In an embodiment of the process step described, the pellets are dried, which results in two process variants.
Variant A:
The pellets, which have been frozen at -196~C, are introduced into a freeze-drying plant. The tempera-tures selected are from 15~C below the sublimation point of water at a pressure of 0.1 Pa to 103 Pa (0.001 to 1.03 mbar). The drying process, which proceeds in a conventional freeze-drying plant (condenser temperature -40~C) at -25~C and 33 Pa (0.33 mbar) in primary drying with sublimation of the matrix water, which has been frozen in amorphous form by means of shock-frosting, results in an end product having a highly porous network structure after secondary drying (desorption). In com-parison with conventionally freeze-dried goods, such pellets are particularly readily soluble and preferably suitable for the development of instant preparations.
Variant B:
The frozen pellets are defrosted and conven-tionally dried. This process can be carried out advan-tageously in vacuo (3000-5000 Pa (30-50 mbar)) to accelerate the drying process and to maintain low tem-peratures. Drying temperatures of up to 50~C may beselected, the temperature during the drying process in the pellet matrix not rising to above 30~C due to the evaporation enthalpy of the liquid.
In the case of conventionally dried pellets (variant B), sol/gel-forming substances required for the matrix are those which are capable of forming drops in sol form and which, after cryopelleting or defrosting, form a gel which is stable after drying. An addition of plasticizers has a beneficial effect on the formation of uniformly round shaped articles. Pellets which have been prepared in this manner are distinguished by economical preparation and can be employed both in the cosmetic and the pharmaceutical sector.
Compared with the prior art, the process M:AL2740B 18.1.1993 - 21 -according to the invention itself can be carried out, on the whole, with a low degree of maintenance and in an economical fashion.
The pellets according to the invention can be suitable for pharmaceutical purposes, but also peroral or cosmetic purposes.
The following are examples of pharmaceutical uses:
- Peroral unit dosage form (2-12 mm pellets) 10 - Pellets can also be filled directly into hard-gelatin capsules or sachets.
- As a basis for the preparation of tablets, coated tablets and the like.
- The pellets are outst~n~ingly suitable for direct tabletting. The high granulometric accuracy which can be achieved means that there are no dosing problems.
- Instant teas - In sachets, pellets can be offered for the prepara-tion of health-care drink solutions (instant preparation). If plant proteins, plant protein hydrolysates, collagen hydrolysates or gelatin are used whose molecular weight distribution has a maximum of some hundred D up to below 105 D, the pellets according to the invention dissolve in water at room temperature in the course of a few seconds.
Mixtures of a variety of plant extracts or with other active substances are also possible in this form.
The combination of Aloe vera with pharmaceuti-cally active substances, or active substances in dietet-ics (health care), can furthermore contribute to an improved tolerance of these substances, in particular when administered internally. For example, irritation of ZlZ8Z4~
M:AL2740B 18.1.1993 - 22 -the gastric mucosa by acetylsalicylic acid can be reduced effectively by the constituents of the Aloe vera juice, which have a protective action on the mucous membrane.
- Balneotherapeutic products, inhalants for dissolution in hot water - Preparation of ointments, creams, gels and the like for the treatment of wounds, for example in the case of burns and chemical burns and the like - Preparation of adhesive plasters and powders for use on wounds and the like - Pellets of active substance prepared under sterile conditions to be inserted into wounds The following are examples of cosmetic uses:
- Preparation of creams, instant creams, moisturizing emulsions, sun care products, products for use against solar dermatitis, shampoos, toothpastes, soaps, bath products, facial toners - Direct use of pellets for the preparation of facial masks, powders and the like - Use in cosmetics in the dissolved or semi-solid form - Use in cosmetics in combination with other active substances Due to the high variability of the formulae and the preparation processes described, the characteristics of the pellets according to the invention can be adjusted in a very simple manner to suit the intended aim.
A specific matrix formation allows direct use of pellets in solid and semi-solid form, dissolution being effected during application.
By varying the Bloom value of the gelatin X~Z8z42 M:AL2740B 18.1.1993 - 23 -employed according to the invention it is not only possible to control characteristics such as, for example, the dissolution rate of the pellets according to the invention, but also to adjust a desired viscosity of an aqueous solution of these pellets, again to suit the intended aim.
Such pellets have a series of advantages: the plant constituents remain unaltered in unpreserved form compared with liquid extracts or dry extracts prepared in the customary manner.
If plasticizers are added, they have an inimi-table appearance and are, moreover, very acceptable when ingested. Unpleasant flavor is already masked by the matrix components themselves.
They allow an alcohol-free drug preparation for plant extracts to be prepared or they can be employed as homoeopathic globuli. Compared with soft gelatin capsules, the active substance cannot leak. Volatile essential oils are formulated to give a solid preparation. In contrast to commercially available solutions and tinctures, their weight is low, and they can be swallowed easily as unit dosage forms.
The examples which follow are intended to illus-trate the invention in greater detail:
Example 1: Pellets as a bath preparation for a medicinal bath against rheumatic complaints (pharmaceutical appli-cation) 2.5 kg of gelatin, 150 Bloom 1.0 kg of glycerol 6.5 kg of water 375 g of juniper berry oil (essential oil) The gelatin is allowed to pre-swell in the glycerol/water mixture at room temperature for 30 minutes and is then dissolved at 60~C. After the essential oil of juniper berries has been added, the mixture is homogen-ized in an Ultra-Turrax, and the emulsion formed is added dropwise to liquid nitrogen at a temperature of -196~C
via the dosing device shown in Fig. 2. The pellets are dried in the air for 24 hours at 20~C and filled into 2~Z8242 M:AL2740B 18.1.1993 - 24 -containers.
g of these pellets when added to a bath dissolve completely in the warm water, releasing the essential oil. This gives a medicinal bath against rheumatic complaints.
Also advantageous against muscular pain is a mixture of 10 g of these pellets and 10 g of oil of rosemary pellets prepared in the same manner.
Melissa oil can be used to prepare a sedative bath.
To prepare pellets for inhalation, Oleum Pini Pumilionis is employed, and the pellets are dissolved in hot water before inhalation.
,Example 2: Vitamin E emulsion pellets, freeze-dried for use in a protective cream (cosmetic use) 0.15 kg of vitamin E obtained from wheatgerm oil 1.0 kg of collagen hydrolysate, molecular weight 13,000 - 18,000 g/mol 9 kg of water The collagen hydrolysate is dissolved in water at room temperature, and the liquid vitamin E is added while homogenizing in an Ultra-Turrax. The resulting emulsion is added dropwise to liquid nitrogen at -196~C via the dosing device as shown in Fig. 2 and shock-frosted in this manner. The water is then removed from the pellets by freeze-drying.
The dried pellets are incorporated into the following protective cream as "solid" vitamin E:
Lipid phase:
TegomulsR 90S 2.5 kg Soybean oil 5.0 kg Cocoa butter 1.5 kg Cetyl alcohol 1.5 kg Aqueous phase:
Distilled water 3.0 kg Active substance:
Vitamin E 30 g which correspond to 230 g of vitamin E emulsion pellets The pellets are emulsified with 1.8 1 of water.
Z~ z8z4z M:AL2740B 18.1.1993 --25 -The components of the lipid phase are melted at 65~C, and mixed with 1.2 kg of the water, which has been heated to the same temperature, with stirring, until a homogeneous mixture has formed. After the cream has S cooled to 30~C, the vitamin E/collagen hydrolysate emulsion is stirred in.
Example 3: Echinacea pellets, unit doage form Original echinacea tincture 2.16 kg Collagen hydrolysate, mean molecular weight 3000 g/mol 0.50 kg Distilled water 0.50 kg The collagen hydrolysate is dissolved in water at room temperature and the solution is mixed with the original tincture. The ethanol is removed from the ethanol/water mixture at 40~C under a vacuum of 5000 Pa (50 mbar) in a one-step vacuum evaporator.
The echinacea-contAining solution is added drop-wise to liquid nitrogen at -196~C via a dosing device as shown in Fig. 2, giving the pellets. These pellets are subsequently subjected to freeze-drying with a primary drying step at -50~C and 5 Pa (0.05 mbar) and a secondary drying step at 22~C.
After drying, the echinacea pellets have a diameter of 5 mm. 3xl pellets taken every day corresponds to the dosage as a prophylactic against common colds.
Example 4: Echinacea soft gelatin pellets:
Gelatin (140 Bloom) 250 g Glycerol 100 g Fresh echinacea juice (pressed-out juice) 5000.0 g The gelatin is allowed to swell for 30 minutes in the mixture of fresh plant juice and glycerol, this mixture is heated to 40~C, and such an amount of water that the composition is still flowable is removed under a vacuum at 5000 Pa (50 mbar) in a one-step evaporator at 40~C. The composition is cryopelleted as in Example 1 via a dosing device as shown in Fig. 2 and the pellets are-dried under the conditions indicated. The pellets, which have a diameter of 3.5 mm, are filled into a dosing dispenser. A unit dose of 5 pellets is withdrawn for use 2~28Z4~
M:AL2740B 18.1.1993 - 26 -as a prophylactic.
Example 5: Rutin suspension Gelatin 140 Bloom 200 g Glycerol 150 g 5 Distilled water 650 g Rutin 87.5 g A solution is prepared from gelatin, glycerol and water as described in Example 1, and the rutin is sus-pended in powder form. Pelleting and drying is effected as shown in Example 1. 5 pellets of diameter 3.5 mm contain a dose of 50 mg of rutin.
Example 6: Aloe vera juice 150 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 3000 g of Aloe vera juice, solids concentration 0.6 %
(w/w) Freshly obtained fillets of Aloe vera leaves are homogenized, and the product is purified and filtered.
The collagen hydrolysate is dissolved, with stirring, in the resulting, cooled Aloe vera juice. This solution is then used for forming pellets at -196~C in an immersion bath cont~ining liquid nitrogen, using the CryopelR
feeding device.
The shock-frosted, round shaped articles are dried in a freeze-drying plant where the primary drying step is carried out at -50~C and 5 Pa (0.05 mbar) and the secondary drying step at 22~C.
This gives pellets of diameter 4 mm and an Aloe vera content of 10.7 % (w/w, dry matter). Grading shows a granulometric accuracy of 78 %.
The pellets dissolve completely in water at room temperature in the course of 20 seconds.
, Example 7:
100 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 50 g of mannitol 50 g of wheat protein hydrolysate, molecular weight < 5000 g/mol 2000 g of Aloe vera juice, solids concentration 0.6 %
Z~ 824z M:AL2740B 18.1.1993 - 27 -The collagen hydrolysate, the wheat protein hydrolysate and the mannitol are dissolved in the cold Aloe vera juice, which has been processed as shown in Example 6, and pellets are prepared as shown in Example 6. This gives pellets of diameter 3 mm and an Aloe vera solids content of 5.7 % (w/w). Dissolved in orange juice or passion fruit juice, these pellets can be used as a drink solution.
~Example 8:
200 g of collagen hydrolysate, mean molecular weight:
3000 g/mol 4000 g of Aloe vera juice, 10 x concentrate The Aloe vera juice obtained in Example 6 is brought to a concentration of 10 x at 40~C under a vacuum of 5000 Pa (50 mbar) by means of a one-step vacuum evaporator. The collagen hydrolysate is dissolved in the juice, and lyophilized pellets are prepared after short-term pasteurization. Round shaped articles of diameter 4.5 mm and an Aloe vera solids content of 54.5 % (w/w) are obtained.
The pellets dissolve in water at room temperature in the course of 40 seconds.
5 g of these pellets dissolved in 100 ml of sterile water give an effective instant formula against solar dermatitis.
Example 9:
Incorporation of the pellets according to the invention into a night cream a) Preparation of the pellets 300 g of collagen hydrolysate, mean molecular weight:
13,000-18,000 g/mol 4000 g of Aloe vera juice, solids concentration 0.6 %
Lyophilized pellets with an Aloe vera solids content of 7.4 % (w/w) are prepared as described in Example 6.
b) Night cream formula Lipid phase:
200 g of Tegomuls 90S
750 g of avocado oil 2~28~4;~
M:AL2740B 18.1.1993 - 28 -Aqueou~ phase:
200 g of native collagen (3 % solution, molecular weight 300,000 g/mol) 30 g of elastin 32 g of Aloe vera pellets as described under a) 3000 g of freshly distilled water The lipid phase is melted at 70~C. The water is also heated to 70~C, and the elastin is dissolved there-in. The resulting aqueous solution is homogenized in the lipid phase. The cream base is cooled to 35~C. The Aloe vera pellets are dissolved in the cold collagen solution and dispersed homogeneously in the cream base.
Example 10:
400 g of commercially available gelatin (170 Bloom) 300 g of glycerol (85 %) 1300 g of Aloe vera juice, solids concentration 0.5 %
(w/w) The gelatin powder is added to the freshly obtained and homogenized Aloe vera juice and allowed to pre-swell for approximately 45 minutes. The mixture is subsequently dissolved completely at 40~C, and the glycerol is admixed to give a homogeneous mixture.
The solution, which has a temperature of 40~C, is subsequently dosed into the immersion bath cont~in;ng liquid nitrogen via the pump in the plant shown in Fig. 2, and pellets are made. The deep-frozen, round shaped articles are defrosted and dried at a rising temperature at between 25~C and 40~C. The pellets have a residual moisture content of 10 % and are storage-stable.
The pellets which have been prepared in this manner can be incorporated into a commercially available hydrogel (for example polyacrylate gel). The pellets swell in the hydrogel after 10 to 15 minutes up to twice their original size and form gel-like, readily meltable shaped articles which dissolve after application to the skin.
Alternatively, the pellets can also be added directly to the hydrogel without drying and without intermediate storage.
Claims (37)
1. A shaped article containing plant extract, which comprises a dispersion of the plant extract in a matrix composed predominantly of a skeleton builder of hydrophilic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, elastin hydrolysates, plant proteins, plant protein hydrolysates; and their mixtures.
2. A shaped article as claimed in claim 1, wherein the hydrophilic macromolecule is a thermoreversible sol/gel forming agent.
3. A shaped article as claimed in claim 1, wherein the matrix contains an additional skeleton builder from the group consisting of: albumins, plant proteins, plant protein hydrolysates, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, dextran, sugars, glycine, lactose, sorbitol, mannitol or polyvinylpyrrolidone.
4. A shaped article as claimed in claim 3, wherein the matrix contains less than 50 % by weight of additional skeleton builder.
5. A shaped article as claimed in claim 1, which comprises a pharmaceutically acceptable auxiliary or carrier for the matrix.
6. A shaped article as claimed in claim 1, which contains 0.1 - 98 % by weight (calculated as dry substance) of plant extract.
7. A shaped article as claimed in claim 1, wherein the plant extract is selected from the group consisting of:
solid plant extracts, liquid plant extracts, hydrophilic plant extracts, lipophilic plant extracts, individual plant constituents; and their mixtures.
solid plant extracts, liquid plant extracts, hydrophilic plant extracts, lipophilic plant extracts, individual plant constituents; and their mixtures.
8. A shaped article as claimed in any one of claims 1-7, wherein the plant extract is Aloe vera juice.
9. A shaped article as claimed in claim 1, in the form of a lyophilisate.
10. A shaped article as claimed in claim 1, which is rapidly dissolving and wherein the matrix is composed of essentially a plant protein, plant protein hydrolysate, collagen hydrolysate, a gelatin derivative which is soluble in cold water, or gelatin whose molecular weight distribution has a maximum of below 105 D.
11. A shaped article as claimed in claim 1, wherein the matrix contains 1-50 % by weight (based on the composition to be processed) of the plasticizers glycerol or sorbitol and masking flavors.
12. A shaped article as claimed in claim 11, in solid, semi-solid or gel-like form.
13. A shaped article as claimed in claim 12, in the form of a pellet.
14. A shaped article as claimed in any one of claims 2-13, wherein the sol/gel forming agent is a gelatin whose molecular weight distribution has a maximum of above 10 5 D.
15. A process for the preparation of shaped articles containing plant extract, wherein a) a skeleton builder of hydrophilic macromolecules selected from the group consisting of: collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant proteins, plant protein hydrolysates, elastin hydrolysates; and their mixtures, is mixed with plant extracts selected from the group consisting of:
hydrophilic liquid plant extracts, aqueous extracts, alcoholic extracts; and their mixtures; and b) the resulting mixture of skeleton builder and plant extract is added dropwise to an intensely cold inert liquefied gas, thus making it into shaped articles.
hydrophilic liquid plant extracts, aqueous extracts, alcoholic extracts; and their mixtures; and b) the resulting mixture of skeleton builder and plant extract is added dropwise to an intensely cold inert liquefied gas, thus making it into shaped articles.
16. A process as claimed in claim 15, wherein a sol/gel forming agent is employed as skeleton builder.
17. A process as claimed in claim 15 or 16, wherein the shaped article prepared is a pellet.
18. A process as claimed in any one of claims 15 to 17, wherein the plant extract employed is Aloe Vera juice.
19. A process as claimed in any one of claims 15 to 17, wherein the pellets obtained in step b) are incorporated directly into a cream or hydrogel base.
20. A process as claimed in claim 17, wherein the pellets are freeze-dried.
21. A process as claimed in claim 15, wherein a solution of the skeleton builder is prepared in step a) and mixed with the hydrophilic liquid plant extract.
22. A process as claimed in claim 15, wherein the organic solvent is removed in the event that alcoholic extracts are used.
23. A process as claimed in claim 15, wherein the solution is concentrated in step a).
24. A process as claimed in claim 15, wherein a lipophilic extract is emulsified in the matrix, or a solid plant extract is suspended or dissolved in the matrix in step a).
25. A process as claimed in claim 15, wherein the mixture obtained is added dropwise to liquid nitrogen.
26. A process as claimed in claim 15, wherein an additional skeleton builder from the group consisting of:
albumin, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, dextran, sugars, glycine, lactose, mannitol or polyvinylpyrrolidone is added to the dispersion of skeleton builder and plant extract.
albumin, agar-agar, gum arabic, pectins, tragacanth, xanthan, natural and modified starches, dextrans, dextrins, maltodextrin, chitosan, alginates, cellulose derivatives, dextran, sugars, glycine, lactose, mannitol or polyvinylpyrrolidone is added to the dispersion of skeleton builder and plant extract.
27. A process as claimed in claim 15, wherein 1-50% by weight (based on the composition to be processed) of the platicizers glycerol and sorbitol or their mixtures are added to the mixture of skeleton builder and plant extract.
28. A process as claimed in claim 15, wherein gelatin whose molecular weight distribution has a maximum of above 10 5 D is mixed with the plant extract at not more than 60°C
to act as skeleton builder.
to act as skeleton builder.
29. A process as claimed in claim 28, wherein liquid Aloe Vera juice is mixed with gelatin at not more than 40°C.
30. A process as claimed in any one of claims 15 to 29, wherein the shaped articles are dried at not more than 50° C.
31. Use of the shaped articles as claimed in claim 1 for the preparation of a pharmaceutical dosage form.
32. Use of the shaped articles as claimed in claim 1 for the preparation of a peroral dosage form.
33. Use of the shaped articles and claimed in claim 2 for the preparation of a cosmetic product.
34. A pharmaceutical dosage form containing shaped articles as claimed in claim 1.
35. A food preparation (health care) containing shaped articles as claimed in claim 1.
36. A cosmetic product containing shaped articles as claimed in claim 1.
37. A shaped article containing Aloe Vera juice, which comprises a dispersion of the Aloe Vera juice in a matrix predominantly composed of skeleton builders of hydrophilic macromolecules selected from the group consisting of:
collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant proteins, plant protein hydrolysates, elastin hydrolysates and their mixtures.
collagen, gelatin, fractionated gelatin, collagen hydrolysates, gelatin derivatives, plant proteins, plant protein hydrolysates, elastin hydrolysates and their mixtures.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4201179.5 | 1992-01-17 | ||
| DE4201179A DE4201179A1 (en) | 1992-01-17 | 1992-01-17 | Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc. |
| DEP4201172.8 | 1992-01-17 | ||
| DE4201172A DE4201172C1 (en) | 1992-01-17 | 1992-01-17 | Pellets contg. Aloe vera extract - useful, e.g. as antiinflammatory of antibiotic agents, or for treating gastric ulcers |
| US07/876,866 US5401502A (en) | 1992-01-17 | 1992-04-30 | Pellets containing plant extracts, process of making same and their pharmaceutical peroral or cosmetic use |
| US07/876,866 | 1992-04-30 | ||
| US07/876,876 US5387415A (en) | 1992-01-17 | 1992-04-30 | Aloe vera juice containing pellets process for production thereof and the use thereof as pharmaceutical, cosmetic and peroral agents |
| US07/876,876 | 1992-04-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2128242A1 CA2128242A1 (en) | 1993-07-22 |
| CA2128242C true CA2128242C (en) | 1998-09-22 |
Family
ID=27435368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002128242A Expired - Fee Related CA2128242C (en) | 1992-01-17 | 1993-01-18 | Moulded bodies, in particular pellets, containing one or more plant extracts, and the pharmaceutical or cosmetic use of such pellets |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0620727B1 (en) |
| JP (1) | JPH07502735A (en) |
| AT (1) | ATE151631T1 (en) |
| AU (1) | AU679905B2 (en) |
| CA (1) | CA2128242C (en) |
| DE (1) | DE59306197D1 (en) |
| DK (1) | DK0620727T3 (en) |
| ES (1) | ES2102637T3 (en) |
| GR (1) | GR3024062T3 (en) |
| WO (1) | WO1993013754A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2348895A4 (en) * | 2008-07-18 | 2015-03-04 | Cargill Inc | Frozen pellets made with juice |
| US9861115B2 (en) | 2003-04-11 | 2018-01-09 | Cargill, Incorporated | Pellet systems for preparing beverages |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0621777T3 (en) | 1992-01-17 | 1996-10-21 | Alfatec Pharma Gmbh | Pellets containing active substance and with a matrix of hydrophilic macromolecules, and process for their preparation |
| DE19603019C2 (en) * | 1996-01-17 | 1998-10-15 | Lancaster Group Gmbh | Cosmetic skin cleanser based on natural ingredients |
| IL131317A (en) * | 1999-08-09 | 2006-08-01 | Cts Chemical Ind Ltd | Binder for pharmaceutical compositions |
| JP2003160440A (en) * | 2001-11-26 | 2003-06-03 | Mikimoto Pharmaceut Co Ltd | Pearl layer powder |
| US9023333B2 (en) | 2002-10-16 | 2015-05-05 | Stefan Frahling | Method of using shaped articles to apply a scaffold-forming agent to an external skin and/or hair surface of a human or an animal |
| ES3034291T3 (en) | 2022-02-21 | 2025-08-14 | Biofactoria Naturae Et Salus Sa | Single-dose cosmetic product and process of manufacturing thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE454386C (en) * | 1924-05-27 | 1928-01-06 | Chemische Produkte Vormals H S | Process for the production of pharmaceutical and dietetic preparations in spherical form |
| GB242323A (en) * | 1924-07-04 | 1925-11-04 | Firm Knoll & Co Chem Fab | An improved method of manufacturing medicinal jujubes |
| GB887901A (en) * | 1960-04-13 | 1900-01-01 | ||
| FR1397583A (en) * | 1964-05-04 | 1965-04-30 | Hoffmann La Roche | Process for the preparation of compositions containing substances sensitive to oxidation |
| BE770604A (en) * | 1971-07-28 | 1971-12-01 | Hoffmann La Roche | High potency vitamin e powders |
| US5215756A (en) * | 1989-12-22 | 1993-06-01 | Gole Dilip J | Preparation of pharmaceutical and other matrix systems by solid-state dissolution |
-
1993
- 1993-01-18 AU AU33431/93A patent/AU679905B2/en not_active Ceased
- 1993-01-18 EP EP93902033A patent/EP0620727B1/en not_active Expired - Lifetime
- 1993-01-18 ES ES93902033T patent/ES2102637T3/en not_active Expired - Lifetime
- 1993-01-18 DK DK93902033.5T patent/DK0620727T3/da active
- 1993-01-18 DE DE59306197T patent/DE59306197D1/en not_active Expired - Lifetime
- 1993-01-18 WO PCT/DE1993/000037 patent/WO1993013754A1/en not_active Ceased
- 1993-01-18 CA CA002128242A patent/CA2128242C/en not_active Expired - Fee Related
- 1993-01-18 JP JP5512078A patent/JPH07502735A/en active Pending
- 1993-01-18 AT AT93902033T patent/ATE151631T1/en not_active IP Right Cessation
-
1997
- 1997-07-09 GR GR970401718T patent/GR3024062T3/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9861115B2 (en) | 2003-04-11 | 2018-01-09 | Cargill, Incorporated | Pellet systems for preparing beverages |
| EP2348895A4 (en) * | 2008-07-18 | 2015-03-04 | Cargill Inc | Frozen pellets made with juice |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0620727A1 (en) | 1994-10-26 |
| EP0620727B1 (en) | 1997-04-16 |
| DE59306197D1 (en) | 1997-05-22 |
| WO1993013754A1 (en) | 1993-07-22 |
| AU3343193A (en) | 1993-08-03 |
| DK0620727T3 (en) | 1997-05-26 |
| AU679905B2 (en) | 1997-07-17 |
| JPH07502735A (en) | 1995-03-23 |
| ES2102637T3 (en) | 1997-08-01 |
| CA2128242A1 (en) | 1993-07-22 |
| GR3024062T3 (en) | 1997-10-31 |
| ATE151631T1 (en) | 1997-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5578307A (en) | Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use | |
| US5401502A (en) | Pellets containing plant extracts, process of making same and their pharmaceutical peroral or cosmetic use | |
| US5387415A (en) | Aloe vera juice containing pellets process for production thereof and the use thereof as pharmaceutical, cosmetic and peroral agents | |
| US5558880A (en) | Pharmaceutical and other dosage forms | |
| JP3107566B2 (en) | Formation of pharmaceutical and other matrix systems by solid state dissolution. | |
| US6103269A (en) | Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies | |
| RU2131244C1 (en) | Hard dozed form | |
| KR101433962B1 (en) | Method for solubilising, dispersing and stabilising of substances, products manufactured according to the method as well as the use thereof | |
| CA2128244C (en) | Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies | |
| CN105395469A (en) | Freeze-dried Composition Of Active Substances | |
| CN101919805B (en) | Freeze-dried molded products containing magnesium ascorbyl phosphate | |
| CA2128242C (en) | Moulded bodies, in particular pellets, containing one or more plant extracts, and the pharmaceutical or cosmetic use of such pellets | |
| CN101904813A (en) | Freeze-dried coated mechanograph | |
| CN107468528A (en) | A kind of lyophilized formulations and preparation method thereof | |
| CN106881028B (en) | Freeze-dried preparation dissolving device | |
| WO2005034973A1 (en) | Capsulated herbal composition as auxilary medicament against diabetes mellitus type (i) and (ii) | |
| AU677198C (en) | Pharmaceutical and other dosage forms | |
| CN109106736A (en) | A kind of lyophilized excipient containing plant tissue | |
| JPH0678225B2 (en) | Dehydrated medicine and its manufacturing method | |
| CN109106737A (en) | A kind of lyophilized excipient containing plant tissue | |
| IE904520A1 (en) | Preparation of pharmaceutical and other matrix systems by¹solid-state dissolution | |
| HK1011279B (en) | Preparation of pharmaceutical and other matrix systems by solid-state dissolution | |
| HK1087637A (en) | Use of molded bodies for external application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |